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The efficacy of antidepressants is tested in randomized controlled trials (RCTs). RCTs report 
rather modest remission rates when it comes to the efficacy of serotonin reuptake inhibitors 
(SSRIs) (Keller et al., 1998; Trivedi et al., 2006). For instance, an RCT with the SSRI sertraline 
in chronically depressed patients yielded a response rate of 22% (i.e. reduction of symptoms 
of at least 50%) and a remission rate of 36% (i.e. symptom reduction below the threshold 
of disorder) after 12 weeks (Keller et al., 1998). The response rate of outpatients with major 
depressive disorder (MDD) to treatment with the SSRI citalopram in an observational study 
was 47%, while the remission rate was only 28-33% after 8 weeks of treatment (Trivedi et al., 
2006). Overall, this leaves ± 50% of MDD patients who do not respond to antidepressants 
(Keller et al., 1998; Trivedi et al., 2006). Meta-analysis of RCTs have also indicated that 
antidepressants improve the symptoms of depression, but the difference with placebo is 
small and may only be clinically worthwhile in severely depressed patients (where placebo is 
less effective) (Khan et al., 2002; Kirsch et al. 2008; Fournier et al., 2010). 
A complementary tool to predict efficacy of novel antidepressant drug
Although much research effort has been put into the development of new antidepressant 
drugs, the process of developing a drug often fails at the stage of large RCTs in which an 
initially promising compound appears to lack efficacy after all  (Harmer et al., 2011). Several 
experimental medicine models have been proposed as preclinical tools in order to predict 
drug efficacy before the stage large RCTs (Dawson et al., 2011). Experimental medicine 
models focusing on antidepressant drug development tap into a range of biomarkers 
underlying the defective processes seen in MDD patients including behavioural measures, 
electroencephalogram (EEG), Magnetic Resonance Imaging (MRI) and sleep physiology 
(Pangalos et al., 2007; Dawson et al., 2011 ). 
Among the various experimental medicine models, the cognitive neuropsychological model 
has been proposed as a complementary tool to predict the efficacy of antidepressant 
drug even before the stage of large scale and expensive RCTs (Harmer et al., 2009; 2011). 
Despite the fact that antidepressants may take weeks to show a clinical effect in depressed 
patients, they do have immediate effects on emotional information processing, even after 
single doses in healthy volunteers (Harmer et al., 2003; Harmer et al., 2008; Arnone et al., 
2009; Murphy et al., 2009; Rawlings et al., 2010). The neuropsychological model of drug action 
aims to measure early antidepressant effects by detecting the shift from a negative to a more 
positive bias in different domains of emotional information processing such as attention, 
memory and processing of emotional facial expressions (reviewed by Harmer et al., 2009). 
Some markers of depression that are present in remitted patients are also detectable 
through pharmacological challenges in healthy individuals (Harmer et al., 2003; Harmer et 
al., 2008; Arnone et al., 2009; Murphy et al., 2009; Rawlings et al., 2010). Furthermore, healthy 







antidepressants is not contaminated by earlier pharmacological treatment. These attributes 
of healthy individuals makes them suitable for assessing the effects of interventions in 
experimental psychological settings.
Cognitive neuropsychological model of drug action
Antidepressants may take 6-12 weeks to elicit a clinically observable reduction of depressive 
symptoms in MDD patients (Frazer and Benmansour 2002). Antidepressants do have 
immediate biological effects as several processes (e.g. increasing the amount of serotonin 
in the synaptic cleft by blockade of transporters) are directly initiated at the molecular level 
(Berton and Nestler 2006; Stahl et al., 2013).  Already in the early stage of antidepressant 
administration these direct biological effects lead to the initiation of downstream neuro-
adaptive processes but also to a shift from a negative to a positive bias in information 
processing. According to the neuropsychological model of drug action, these induced 
changes in information processing interact with emotional and social cues from the 
environment, resulting over the course of time in an effect on mood states (Figure 1). This 
gives an alternative (complementary) explanation for the delay in clinically observable 
antidepressant effects. The early shift towards positive emotional processing is proposed to 
be associated with neural fine-tuning in subcortical and cortical circuits (Review, Harmer et 





















Figure 1. a) Mechanisms underlying the delay in antidepressant drug action as it is generally 
accepted; b) Mechanisms underlying the delay of drug action as it described in the 
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Figure 1. a) Mechanisms underlying the delay in antidepressant drug action as it is generally accepted; 
b) Mechanisms underlying the delay of drug action as it described in the neuropsychological model of drug 
action by Harmer et al., 2009.
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Validation of the cognitive neuropsychological model of drug action 
The cognitive neuropsychological model of drug action has been validated in healthy 
volunteers by means of behavioural tasks and neural measures, assessing different domains of 
emotional information processing following administration of conventional antidepressant 
drugs which act on different neurotransmitter systems (Harmer et al., 2003; Harmer et al., 
2008; Arnone et al., 2009; Norbury et al., 2007; Murphy et al., 2009; Rawlings et al., 2010). 
Drug administration and early behavioural changes 
Two hours following a single dose of the tetracyclic antidepressant mirtazapine (15 mg), 
healthy volunteers were less accurate in recognizing fearful faces during a facial expression 
recognition task (FERT) without affecting reaction times (Arnone et al., 2009). Mirtazapine 
increased reaction times to self-referential words in general, and specifically improved the 
recall of positive self-referential words during an Emotional Categorization and Memory 
Task, which is another component of the Emotional Test Battery (ETB) (Arnone et al., 2009). 
In another study a single dose of the noradrenergic antidepressant reboxetine (4 mg) 
improved the recall of happy facial expressions only 2 hours after administration in healthy 
volunteers (Harmer et al., 2003). In addition, the reboxetine group had a faster reaction time 
towards positive vs negative self- referential words, while this difference was much smaller in 
the placebo group during the Emotional Categorization Task (Harmer et al., 2003). 
The ETB was also completed by healthy volunteers 6 hours after administration of a single 
dose of the serotonin-norepinephrine reuptake inhibitor duloxetine (60 mg) (Harmer et al., 
2008). Duloxetine improved the recognition of both disgust and happy facial expressions 
without affecting reaction times (Harmer et al., 2008). 
These findings provide evidence for early changes in the behavioural response to emotional 
stimuli following antidepressant drugs administration, however, the interpretation of the 
changes found on the behavioural measures may vary. 
Drug administration and early neural changes 
Next to the early detection of changes in emotional processing and biases by means of 
behavioural measures following antidepressant treatment, early changes at a neural level 
can also be detected by means of neuroimaging techniques measuring neuronal activity. 
Neuronal activity is accompanied by an increase in oxygenation metabolism, cerebral blood 
flow and volume. MRI is an imaging technique that measures these changes in blood flow 
and provides an indirect measure of neuronal activity in the brain.  
A single dose of mirtazapine (15 mg) vs placebo was associated with a differential neural 
response to emotional faces in healthy volunteers two hours after administration (Rawlings et 







faces in brain regions involved in emotional processing such as the amygdala, hippocampus 
and fronto-striatal cortex (Rawlings et al., 2010). 
Reboxetine administration (8 mg daily for seven days) in healthy volunteers was associated 
with decreased neural response to subliminally presented fearful faces in the right amygdala 
and with increased activation in the right fusiform gyrus to subliminally presented happy 
faces (Norbury et al., 2007).  
Furthermore, a single dose of the SSRI citalopram (20 mg) reduced the neural response to 
fearful faces in the amygdala of healthy individuals, while it did not affect the response to 
happy and neutral facial expressions (Murphy et al., 2009). 
Thus, the findings on the neural response to emotional stimuli following antidepressant 
drugs administration seems to be more unequivocal compared to the findings on the 
behavioural response.   
The majority of the aforementioned studies investigated the acute effect of various 
antidepressants on emotional information processing (i.e. on behaviour and neural 
responses) and reported differences between the antidepressant vs placebo groups in 
absence of changes in mood or subjective state (Harmer et al., 2003; Norbury et al., 2007; 
Murphy et al., 2009; Rawlings et al., 2010). The findings indicate a positive shift in emotional 
information processing. These observations may be interpreted as evidence for the cognitive 
neuropsychological model which hypothesizes that early changes in emotional bias precede 
the improvement in mood following antidepressant treatment (Harmer et al., 2009). Since 
single or short-term administration of antidepressant drugs already have a detectable 
effect in healthy volunteers, the ETB has been applied as a tool to investigate whether new 
compounds such as GSK424887 (NK1 antagonist and serotonin reuptake inhibitor) (Harmer 
et al., 2013) and erythropoietin (Miskowiak et al., 2007a; Miskowiak et al., 2007b) may have 
antidepressant effects. As mentioned above, this approach implements a potential new step 
in the development of new antidepressant drugs. This might improve the efficiency of the 
registration process, as initially promising compounds in animals often fail to be effective in 
depressed patients (Review, Harmer et al., 2011). 
In addition to the altered neural and cognitive responses to emotional information, altered 
resting-state connectivity is associated with MDD and may contribute to its pathophysiology. 
Several pharmacological studies have investigated the effect of conventional antidepressant 
drugs on connectivity within the affective networks associated with MDD (Anand et al., 2005; 
McCabe and Mishor, 2011; van Wingen et al., 2014). These studies have mainly focussed on 
abnormalities in the cortico-limbic mood regulating circuit (MRC), the default-mode network 
(DMN) and the task-positive network (TPN) as these have been reported to be altered in 
depressed patients (reviewed by Wang et al., 2012). Pharmacological resting-state studies 
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conducted with conventional antidepressant drugs in healthy individuals reported reduced 
connectivity within the cortico-limbic network (McCabe and Mishor et al., 2011) and reduced 
connectivity in DMN and TPN, the latter two networks are thought to be increased in MDD 
patients (Greicius et al., 2007; Wang et al., 2012). 
Structure of this dissertation 
The studies presented in this thesis concern two projects. In both projects we applied 
the cognitive neuropsychological model of drug action to test antidepressant effects of a 
compound in healthy volunteers. In the second project, concerning a well-known compound 
(L-tryptophan), we further investigated the model by tapping into HPA-axis reactivity and 
social decision making as additional outcomes, and investigated their interaction with a 
genetic marker. In the first project, concerning a novel compound (ARA290), we used not only 
behavioural/cognitive measures but also neuroimaging to detect antidepressant effects. 
Pharmacological compound ARA290
Erythropoietin (EPO) is an endogenous protein of which the primary function is to regulate 
the proliferation of hematopoietic stem cells into red blood cells (erythropoiesis). Next 
to its role in erythropoiesis, EPO plays a role in tissue protection and repair through anti-
inflammatory actions (Brines and Cerami, 2005). EPO administration in animal models of 
clinical conditions involving tissue damage such as experimental brain damage (Brines 
et al., 2000) and neonatal stroke (Gonzalez et al., 2009) have shown that EPO crosses the 
blood brain barrier (BBB) and exerts neurotrophic actions. In humans, administration of 
EPO improved cognitive performance of patients with multiple sclerosis and schizophrenia 
(Ehrenreich et al., 2007a; 2007b).
Based on these beneficial effects of EPO on brain tissue and cognition, a series of studies 
have been conducted to investigate the antidepressant-like effects of EPO, using the 
neuropsychological model of drug action (Miskowiak et al., 2007a; Miskowiak et al., 2007b). 
The first studies were in healthy volunteers and later in patients with MDD (Miskowiak et 
al., 2009; 2010). Although the results of these studies did suggest that a single dose of EPO 
administration may have antidepressant effects, its utilization as antidepressant drug is 
rather limited due to hematopoietic side effects of repetitive EPO administration (Wolf et 
al., 1997; Stohlawets et al., 2000). However, the hematopoietic and tissue protective roles of 
EPO are regulated by two distinct receptor systems (Figure 2). ARA290 is an 11-amino acid, 
linear peptide developed as an EPO analogue, which solely acts on a specific receptor (i.e. 
Innate Repair Receptor; IRR) that initiates tissue protective and anti-inflammatory actions. 
The IRR consist of a β-common receptor (βCR) subunit (CD131) coupled to an EPOR and its 
activation  initiates multiple signalling pathways resulting tissue protective actions, without 







elimination half-life of approximately 2 minutes following i.v. administration (Niesters et al., 
2013). Despite the short elimination half-life, ARA290 is suggested to elicit durable effects 
due to the activation of IRR which regulates the innate tissue-protective response in various 
stages over a period from hours to days (Brines et al., 2008a; Brines and Cerami, 2012).
The lack of hematopoietic effects makes ARA290 suitable for repetitive administration and 
- if similar antidepressant-like effects are found as was reported with EPO administration – 
more promising to develop into an effective antidepressant drug. In Chapter 2 and 3, the first 
studies testing potential antidepressant-like effects of ARA290 in humans will be described. 
Specifically, effects of ARA290 on behavioural measures (emotional information processing) 















Figure 2. ARA 290 is acting on the EPO-R-CD131 receptor to initiate tissue protection 
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Figure 2. ARA290 is acting on the EPO-R-CD131 receptor to initiate tissue protection (adapted from Brines and 
Cerami, 2012, The receptor that tames the innate immune response). 
Dietary compound: L-tryptophan 
Reduced serotonergic activity is involved in the pathophysiology of depression (reviewed 
by Nestler et al., 2002). Experimental manipulations of serotonin in humans, for instance 
by means of acute tryptophan depletion, have been extensively used in order to shed light 
on its role in depression (Review, Booij et al., 2003). Acute Tryptophan Depletion (ATD) is 
an dietary intervention in which deprivation of L-tryptophan (the amino acid precursor of 
serotonin) causes a transient state of reduced serotonergic activity. ATD affects mood and 
cognition in a subgroup of remitted patients treated with SSRIs and recovered depressed 
patients in a manner that is consistent with a depressogenic effect (Review, Booij et al., 2003). 
Since reducing levels of tryptophan may induce (transient) depressive symptoms, dietary 
interventions that increase tryptophan have been used in order investigate whether opposite 
effects on mood and cognition can be achieved (Booij et al., 2006; Markus et al., 2008). This 
approach has been applied in depression vulnerable populations defined by, for instance, 
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high neuroticism scores, high cognitive reactivity scores or s-carriers of the 5-HTTLPR genotype 
(Markus et al., 1998;Firk and Markus, 2009; Markus and Firk, 2009).  One of the multiple dietary 
interventions to increase plasma Tryptophan/Large Neutral Amino Acids ratio (TRP/LNAA) – 
an index of central serotonin availability – is to administer pure L-tryptophan (Tryptophan) 
capsules (Markus et al., 2008). Tryptophan is an amino acid present in nutrients and is daily 
ingested as part of our diet (World Health Organization, 2002). Besides being the precursor 
of serotonin, tryptophan is metabolized in various tissues in the periphery and has multiple 
physiological functions (Le Floc’h et al., 2011). Approximately 90% of ingested tryptophan 
found in blood and plasma is bound to albumin (Madras et al., 1974; Pardridge 1979). The 
remaining 10% of free tryptophan in plasma is available for transport through the BBB 
into the extracellular fluid and cerebrospinal fluid of the central nervous system (CNS) (Le 
Floc’h et al., 2011). Transport through the BBB is facilitated by transporters embedded in 
the capillaries of the BBB. These transporters are shared with Large Neutral Amino Acids 
(LNAA), therefore, the transportation of tryptophan into the CNS is under influence of the 
TRP/LNAA ratio in plasma (Le Floc’h et al., 2011). Once tryptophan has crossed the BBB it is 
taken up by cells within the CNS, and is used for i.e. serotonin synthesis as depicted in Figure 
3. The synthesis of serotonin is dependent on the amount of tryptophan entering the brain 
as the rate limiting enzyme, Tryptophan hydroxylase is not saturated at physiological levels 
of tryptophan in the brain (Le Floc’h 2011; Silber and Schmitt 2010). 
Chapter 4 and 5 describes two studies based on the premise that increasing dietary 
tryptophan intake will increase TRP/LNAA ratio and as a consequence serotonin availability 
in the brain. The effect of increasing serotonin availability in a genetically  vulnerable (i.e. 
5-HTTLPR genotype) group was expected to attenuate the physiological response to social 
stress (i.e. HPA-axis response) and to attenuate the regulation of emotions in response to 
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Serotonin transporter polymorphism and vulnerability to depression 
One of the genetic variations found to be related to depression which has been studied 
extensively is an allelic variation in the promoter region of the serotonin transporter gene: 
the serotonin transporter polymorphism (Heils et al., 1996).  The serotonin transporter 
polymorphism is a repetitive sequence in the promoter region consisting of two alleles which 
can be either long or short. The long (L) variant is associated with higher, whereas the short 
(S) variant is associated with lower transcription activity. Depending on the combination 
of the two variants of alleles (i.e. L/L, L/S or S/S) more or less serotonin transporters are 
expressed in the membrane of the presynaptic neurons. The serotonin transporter regulates 
the availability of serotonin in the synaptic cleft by removing and recycling serotonin and 
therefore influences serotonin neurotransmission (Canli and Lesch, 2007). 
The serotonin transporter polymorphism (5-HTTLPR) has been associated with personality 
traits related to anxiety and depression (Lesch et al., 1996). Meta-analysis, however, has 
reported no consistent direct effects of 5-HTTLPR genotype on the anxiety-related personality 
traits such as harm avoidance and neuroticism (Munafo et al., 2009). 
Apart from the direct effect of 5-HTTLPR genotype, its interaction with adverse childhood 
events was associated with the probability of depression and with suicide risk (Caspi et al., 
2003). Despite the mixed results of meta-analyses and reviews on 5-HTTLPR as a vulnerability 
gene for depression (Munafo et al., 2009; Risch et al., 2009; Belsky et al., 2009; Uher & McGriffin 
et al. 2010; Karg et al., 2011) the literature on Gene x Environment (G x E) interactions and the 
modulation of vulnerability markers related to depression by 5-HTTLPR genotype continues 
to expand (Favaro et al., 2014).  
One of these vulnerability markers is the regulation of neuroendocrine responses to stress. 
The association between 5-HTTLPR genotype and HPA-axis reactivity has been of special 
interest due to the interaction of the serotonin system and HPA axis (Fuller, 1990; Porter et al., 
2004) in regulating neuroendocrine responses. The effect of 5-HTTLPR genotype on HPA-axis 
reactivity has been studied by inducing acute (social) stress through exposure to a public 
speaking task and assessing levels of the stress hormone cortisol (Gotlib et al., 2008; Way 
and Taylor 2010). Some studies showed that homozygous S- allele carriers have an increased 
cortisol response to acute stress (Gotlib et al., 2008; Way and Taylor., 2010), whereas Mueller 
et al. (2011) reported the opposite: homozygous L-carriers showed an increased cortisol 
response compared to individuals carrying at least one S allele. A few other studies did not 
find an effect of 5-HTTLPR genotype on HPA-axis reactivity (Wüst et al., 2009; Verschoor and 
Markus, 2011). These inconsistent findings may have been caused by confounding effects of 
gender, type of stressor, time of testing during the day and the use of hormonal contraceptives. 
Despite the inconsistent findings, however, the association between 5-HTTLPR genotype 
and HPA-axis reactivity to stress, with homozygous s-carriers exhibiting an increased cortisol 
response has been confirmed in a meta-analysis (Miller et al., 2013). However, the association 
had a rather small effect size (d = 0.27) (Miller et al., 2013).  
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Chapter 4 of this dissertation describes a study in which the association between 5-HTTLPR 
genotype and cortisol response, as a measure of HPA-axis reactivity, has been investigated. 
We carefully identified and excluded methodological limitations of previous studies that 
investigated the association between 5-HTTLPR genotype and HPA-axis activity, but reported 
inconsistent findings. Specifically, we a) pre-selected participants based on genotype b) 
exposed every participant to the stressor only once to avoid anticipation) c)  and excluded 
possible confounders of the cortisol response (e.g. use of hormonal contraceptives). The strict 
study design and in- and exclusion criteria were expected to facilitate the detection of the 
distinct effect of 5-HTTLPR genotype on the cortisol response. Additionally, we investigated 
whether the hypothesized elevated cortisol response in homozygous s-allele carriers can be 
treated by tryptophan supplementation.
Next to HPA-axis reactivity, the 5-HTTLPR genotype has also been associated with emotional 
processing as a behavioural endophenotype (Perez-Edgar et al., 2010; Antypa et al., 2011; 
Koizumi et al., 2013). Furthermore, the association between serotonin availability and 
the regulation of emotions in social decision making has been shown by studies with 
serotonergic manipulations in healthy individuals (Crockett et al., 2008; 2010). Since variation 
in 5-HTTLPR genotype is associated with altered processing of emotional and socially 
relevant information, and serotonin availability is involved in decision making processes 
in which people have to overcome an emotional reaction, we investigated whether 1) 
5-HTTLPR genotype is associated with altered regulation of emotions in response to unfair 
offers made by others and whether 2) the regulation of emotions in response to unfair offers 
can be altered by tryptophan supplementation (Chapter 5). 
Outline of this thesis 
• Chapter 2 describes a placebo-controlled randomized clinical trial, testing the effect of 
a novel pharmacological intervention, ARA290, on the behavioural and neural measures 
related to emotional information processing  in healthy individuals. 
• Chapter 3 describes a study on the effect of ARA290 versus placebo on resting-state 
connectivity in the same healthy individuals. 
• Chapter 4 describes a placebo-controlled randomized clinical trial, testing the effect of 
a dietary intervention, tryptophan supplementation, on HPA-axis reactivity in healthy 
carriers of the 5-HTTLPR genotype variants.
• Chapter 5 describes the effect of  tryptophan versus placebo on social decision making in 
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Testing the Antidepressant Properties of the Peptide ARA290 
in a Human Neuropsychological Model of Drug Action
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Studies on the cognitive and neural effects of Erythropoietin (EPO) indicate that EPO may have 
antidepressant effects. Due to its hematopoietic effects, EPO may cause serious side‐effects 
with repeated administration if patients are not monitored extensively. ARA290 is an EPO-
analogue peptide without such hematopoietic side-effects but may have neurotrophic and 
antidepressant effects. The aim of this study was to investigate the possible antidepressant 
effects of ARA290 in a neuropsychological model of drug action. 
Healthy participants (N=36) received ARA290 (2 mg) or placebo in a double-blind, 
randomized, parallel-group design. Neural and cognitive effects were assessed one week 
after administration. Primary outcome measures were the neural processing of fearful vs 
happy faces and the behavioural recognition of emotional facial expressions. 
ARA290-treated individuals displayed lower neural responses to happy faces in the fusiform 
gyrus. ARA290 tended to lower the recognition of happy and disgust facial expressions. 
Although ARA290 was not associated with a better memory for positive words, it was 
associated with faster categorization of positive vs negative words. Finally, ARA290 increased 
attention towards positive emotional pictures. No effects were observed on mood and 
affective symptoms.
ARA290 may modulate some aspects of emotional processing, however, the direction and 
the strength of its effects do not unequivocally support an antidepressant-like profile for 
ARA290. Future studies may investigate the effects of different timing and dose. 
Registration Clinical Trial:
Eudract reg. nr: 2010-024364-18; ClinicalTrials.gov Identifier: NCT 02070783  
URL: https://clinicaltrials.gov/ct2/show/NCT02070783?term=02070783&rank=1







Despite the large number of pharmacological treatment options for depression, many 
patients show partial or no recovery, and a significant time-lag for the onset of clinical effects. 
Furthermore, the majority of patients experience side effects such as weight gain and sexual 
dysfunction (Masand and Gupta, 2002). There is a need for the development of treatments 
that target different molecular pathways. 
Erythropoietin (EPO) is a glycoprotein that regulates erythropoiesis. EPO also crosses the 
blood brain barrier (BBB) and has neuroprotective and neurotrophic effects when delivered 
in high doses (Brines et al., 2000; Shingo et al., 2001; Gonzalez et al., 2009). The finding that 
cells in ischemic/hypoxic brain tissue express EPO and its receptor (EpoR) (Sirén et al., 2001) 
has led to studies investigating the role of EPO in different types of brain injuries (reviewed 
by Brines and Cerami, 2005). 
 In humans, long-term administration of high dose EPO improved cognitive 
functions in patients with schizophrenia (Ehrenreich et al., 2007a) and multiple sclerosis 
(Ehrenreich et al., 2007b), whereas lower-dose EPO produced no cognitive benefits 
(Ehrenreich et al., 2007b). The effects were not correlated with changes in haematological 
parameters, suggesting that they were mediated by a mechanism other than that of red 
blood cell increase. In patients with treatment-resistant depression, eight weeks of weekly 
EPO versus saline infusions as augmentation treatment had no effect on clinician-rated 
depression severity (primary outcome), but did have small positive effects on self-rated 
depressive symptoms, quality of life, psychosocial function and cognition (Miskowiak et al., 
2014). Earlier research in healthy volunteers had shown that one dose of EPO vs saline down-
regulates neural response to fearful faces in the fusiform gyrus and reduces the recognition 
of fearful facial expressions (Miskowiak et al., 2007a). EPO increased bilateral hippocampus 
activation during a picture memory task one week after administration (Miskowiak et al., 
2007b), but not three days after administration (Miskowiak et al., 2007c). EPO also caused 
transient improvements in self-reported mood in healthy volunteers which lasted for three 
days (Miskowiak et al., 2007a, Miskowiak et al., 2008). These studies use a neurocognitive 
model of antidepressant drug action (Harmer et al., 2009) which is based on the finding that 
various established antidepressants have immediate effects (after a single dose or short-
term treatment) on emotional information processing in healthy individuals (reviewed by 
Harmer et al., 2009, 2010). These early neurocognitive changes induced by antidepressants 
or by other monoaminergic manipulations may be related to subsequent mood changes 
(Tranter et al., 2009; Booij and Van der Does, 2011).
In summary, there is evidence to suggest that the effects of EPO mimic antidepressant actions 
both at a behavioural and at a neural level. However, the human proof-of-concept studies 
were conducted in relatively small samples. Another limitation is the limited clinical potential 
of EPO to treat depressive symptoms in non-anemic patients, due to the hematopoietic 
actions of EPO with repeated administration (Wolf et al., 1997; Stohlawets et al., 2000). 
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The 11‐amino acid, linear peptide ARA290 is an EPO‐derivative that exerts tissue-protective 
effects but is not a hematopoietic stimulant (Brines et al., 2008). ARA290 exerts anti-
inflammatory actions in animals (Swartjes et al., 2011; Pulman et al., 2013). In humans, 
ARA290 had beneficial effects on neuropathic symptoms in patients with sarcoidosis (Heij et 
al., 2012; Dahan et al., 2013; Niesters et al., 2013). The anti-inflammatory actions of ARA290 
are mediated by the innate repair receptor (IRR). (Niesters et al., 2013). Activation of the IRR 
initiates multiple signalling pathways initiating tissue-protective actions, one of which is 
the inhibition of inflammation-induced apoptosis (Brines and Cerami, 2012). The effects of 
ARA290 on neurocognitive processing of emotional information relevant to depression have 
not yet been assessed. 
The aim of this study was to investigate whether ARA290 produces antidepressant-like 
effects. We carried out a double-blind, randomized placebo-controlled clinical trial in healthy 
volunteers. Primary outcome measures were the accuracy and speed of recognition of facial 
expressions of emotions and the neural processing of emotions, in particular amygdala, 
hippocampal and ventromedial prefrontal cortex (vmPFC) response to viewing fearful versus 
happy facial expressions. These effects were measured one week after administration of 
ARA290. 








Participants were recruited via advertisements at various sites within Leiden University. 
Inclusion criteria were: Dutch-speaking males and females (not pregnant and not 
breastfeeding); age 18-35 years; right-handedness; BMI of 18-33kg/m². Exclusion criteria 
were major physical illness; current or past psychiatric disorder (Mini International 
Neuropsychiatric Interview; M.I.N.I.; Sheehan et al., 1997; Van Vliet et al., 2000); current use 
of medication (including over the counter medication); lifetime use of hard drugs; any use of 
nicotine products in the past week; use of soft drugs in the past three months; use of more 
than 14 alcohol units per week and more than 4 units on any day during the past week; 
general MRI contraindications. Participants received €90 for the whole study. This study 
was approved by the Medical Ethics Committee (METC) of Leiden University Medical Centre 
(LUMC).
Instruments
Affective symptoms and mood states 
Participants filled out the 20-item Positive and Negative Affectivity Schedule (PANAS; state 
version) (Watson et al., 1988), the 14-item Hospital Anxiety and Depression Scale (HADS; 
Zigmond and Snaith, 1983; Spinhoven et al., 1997) and single-item Mood States Scales (MSS; 
0-10) (Sadness, Annoyance, Tension, Cheerfulness, Energy). The time frame of the HADS was 
changed into ‘the past three days’. IQ was estimated with the National Adult Reading Test 
(Nelson, 1982; Schmand et al., 1992).
fMRI tasks 
E-prime v1.0 was used for presentation of fMRI tasks and recording of responses. Task stimuli 
were back-projected on a screen located at the end of the scanner bore, which participants 
could see through a mirror. Description and results of the secondary measure (Picture 
Recognition Task) and Visual Stimulation Condition are described in the Supplementary 
Material.
Facial Expression Processing 
Pictures of fearful and happy facial expressions were taken from the Radboud Faces Database 
(Langner et al., 2010) and were presented in blocks. Eight blocks of fearful (4 blocks) and 
happy (4 blocks) were presented (48 sec/block) in fixed order interspersed with 30 seconds 
of fixation cross. Each block consisted of 16 faces (8 male and 8 female, randomly presented 
within a block) presented for 100ms. After presentation of each face a black screen with a 
white “X” was presented for 2900ms. Responses were only recorded within the first 2000ms 
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after onset of a trial. The starting block (fearful or happy) was randomized, stratified for sex. 
Participants performed a simple gender discrimination task. The task took 11 minutes.
fMRI data acquisition 
Imaging data were acquired on a Philips 3.0-T Achieva MRI scanner using a 32-channel SENSE 
head coil for radiofrequency reception (Philips Healthcare, Best, Netherlands).
Whole-brain fMRI data sets were acquired using T2*-weighted gradient echo planar imaging 
with the following scan parameters: 301 (Facial Expression Processing Task)/170 (Picture 
Recognition Task)/ 137 (Visual Stimulation Condition) volumes; 38 axial slices scanned in 
ascending order; repetition time (TR)= 2200ms; echo time (TE)= 30ms; flip angle= 80˚; FOV= 
220 x 220 mm; 2.75 mm isotropic voxels with a 0.275 mm slice gap. 
A high-resolution anatomical image (T1- weighted ultra-fast gradient-echo acquisition; TR= 
9.76ms; TE= 4.59ms; flip angle= 8˚;140 axial slices; FOV= 224 x 177.33 mm; in-plane resolution= 
0.875 mm x 0.875 mm; slice thickness= 1.2 mm), and a high-resolution T2*-weighted gradient 
echo EPI scan (TR= 2.2 s; TE = 30ms; flip angle= 80˚; 84 axial slices; FOV= 220 x 220 mm; in-
plane resolution= 1.96 x 1.96 mm, slice thickness= 2 mm) were acquired for registration and 
normalization to standard space.
fMRI data pre-processing 
Prior to analyses, all fMRI data sets were submitted to a visual quality control check to ensure 
that no gross artefacts were present in the data. Next, data were analysed using FSL Version 
4.1.6 (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl). 
The following pre-processing steps were applied to the EPI data sets: motion correction 
(Jenkinson et al., 2002), non-brain removal (Smith, 2002), spatial smoothing using a Gaussian 
kernel of 6 mm full width at half maximum (FWHM) for the Facial Expression Recognition and 
Picture Recognition tasks and 8mm FWHM for the Visual Stimulation Condition, grand-mean 
intensity normalization of the entire 4D dataset by a single multiplicative factor, a high-pass 
temporal filter of 165 sec. (i.e., 0.006 Hz) for the Facial Expression Processing Task, 60 sec. (i.e., 
0.017 Hz) for the Picture Recognition Task and 40 sec. (i.e., 0.025 Hz) for the Visual Stimulation 
Condition. Time-series statistical analysis was carried out with local autocorrelation 
correction (Woolrich et al., 2001). fMRI EPI datasets were registered to the high resolution EPI 
image, the high resolution EPI image to the T1-weighted image, and the T1-weighted image 
to the 2 mm isotropic MNI-152 standard space image (T1-weighted standard brain averaged 
over 152 subjects; Montreal Neurological Institute, Montreal, Canada) (Jenkinson and Smith, 
2001; Jenkinson et al., 2002). 






fMRI data analysis 
For each participant, two explanatory variables (EVs) were included in a general linear model, 
representing the Fearful and Happy facial expression blocks. Besides the main effects of both 
expression separately, two other contrasts of interest were defined: Fearful > Happy, Happy 
> Fearful. 
The first-level images of the contrasts of parameter estimates and their corresponding 
variances were registered to standard space and fed into a second level mixed effects group 
analysis (Woolrich et al., 2004). We tested for group main effects (one-sample t-tests) and 
between group effects (independent t-tests). 
The resulting statistic images were cluster corrected for multiple comparisons using an initial 
cluster forming threshold of z>2.0, and a corrected cluster significance of p<.05. For clusters 
or regions where significant effects were observed, mean z-scores were extracted from those 
clusters for each individual participant to create bar graphs for illustration of the effects. The 
Harvard-Oxford cortical and subcortical atlases, available in FSL, were used for anatomical 
reference. 
Region of interest (ROI) analysis:
The bilateral amygdala was selected for the Facial Expression Processing, using the Harvard-
Oxford Subcortical Probability atlas. All regions were thresholded at a 50% probability, 
binarized, and used as pre-threshold masks in the respective group level mixed effects 
analyses. Cluster correction was also used within the ROI (z>2.0, p< .05). 
Emotional Test Battery 
Facial Expression Recognition 
The facial expression recognition task (FERT) used a different set of facial stimuli than the 
one used in the scanner. Pictures of faces from Ekman and Friesen (1976) were presented 
sequentially on a computer screen in randomized order for 500ms. Faces expressed one of 
five emotions: happiness, sadness, fear, anger, or disgust. Participants were instructed to 
identify the emotion by pressing the corresponding key on the response box as quickly and 
accurately as possible. Emotional expressions had been morphed between two standard 
images, 0% (neutral) and 100% (full emotion) in 10% steps. Four examples of every emotion 
at each intensity level (40/Emotion) were presented together with neutral expressions (4 
trials) making a total of 204 stimuli presentations. Accuracy, reaction time for correct choices, 
and misclassifications were recorded. 
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Emotion categorization and memory  
–  Categorization.  Sixty personality characteristics generally considered to be disagreeable 
(e.g., untidy, hostile) or agreeable (e.g., honest, optimistic) were presented on the computer 
screen for 500ms. Positive and negative words were matched in terms of word length, ratings 
of usage frequency. Volunteers were asked to categorize these words as quickly as possible. 
Specifically, they were asked to indicate whether they would be pleased or upset if they 
overheard someone else referring to them as possessing this characteristic. Reaction times 
to positive and negative traits were computed. 
– Free Recall.  Fifteen minutes after completion of the categorization task, participants were 
asked to recall as many of the personality traits as possible within two minutes. Hits (correct 
responses) and intrusions (false responses) were analysed.  
– Recognition.  The 30 disagreeable and 30 agreeable characteristics were intermixed with an 
equal number of distracters that were not presented previously. The number of hits (correct 
recognitions) and reaction times were computed. Sensitivity (d’) and response bias (β) were 
computed as in Tranter et al.,2009.  
Visual-Probe 
Biased attention was assessed using the visual-probe task. Stimulus pictures were selected 
from the International Affective Picture Set (Lang et al.,2005). Sixteen of these had a negative 
valence, 16 a positive valence and 32 were neutral. The categories negative and positive 
valence were matched on arousal ratings (M= 5.7) and differed in valence (M=7.3 for positive, 
M=2.4 for negative). Mean arousal and valence ratings for the neutral pictures were 3.2 and 
5.1, respectively. All stimulus pictures were presented in grayscale. The probes consisted of 
images of either one or two black dots, four pixels wide and high. 
 The task started with a number of practice trials, in which a separate set of neutral 
pictures was used. Practice trials continued until six consecutive trials were correctly 
answered with a minimum of eight trials. The actual assessment was based on 192 trials, 
divided in six cycles of 32 trials. Within each cycle, each positive and negative image was 
randomly selected once and randomly paired with one of the 32 neutral images. Within trials 
of each valence (positive-neutral, negative-neutral), the location of the emotional stimulus, 
the probe identity and the congruency were counterbalanced and randomized. 
 The stimulus display showed two pictures in a horizontal arrangement. Timing of a 
trial was as follows: cross (500ms)- stimuli (500ms)- probe (until response)-  inter trial interval 
(750ms). A short self-paced break was offered every 30 trials. Participants were instructed to 
respond as accurately and as fast as possible.







Randomized, double-blind placebo-controlled, parallel-group study. Randomization was 
carried out in blocks of six, and was stratified for sex. The study was conducted at the LUMC 
and randomization was carried out by the LUMC pharmacy, Leiden. The study included two 
lab visits separated by 6 or 7 days. 
Procedure
First Lab Visit
Participants who showed interest were provided with information by email and underwent 
a brief telephone screening. Upon arrival at the laboratory, participants provided written 
informed consent after the study had been fully explained. Participants underwent a 
screening procedure including the M.I.N.I. interview and a physical examination. Screening 
for alcohol use was done by means of a breath test, drugs screening (QD1 220 Drug card-
Quantum diagnostics,UK) and a pregnancy test (QuickVue-Quidel Corporation San 
Diego,USA) were done by urine tests. Next, participants completed questionnaires and the 
IQ test. After ARA290 or placebo (i.v. 2 mg) administration, the participant was monitored for 
10 minutes. At the end of the session participants were given written and oral instructions for 
the coming week: no nutritional supplements, no drugs or tobacco and limitation of alcohol 
use to 4 units/day with a maximum of 14 units/week. Caffeine intake was forbidden within 
one hour before the second lab visit. Participants received a diary in which they were asked 
to record any violations of these instructions.
Second Lab visit
Upon arrival the participant handed in the diary and was interviewed to check for compliance. 
Following screening for alcohol use, drug use and pregnancy, participants completed 
questionnaires and the Picture Encoding Task (Supplementary Material). Participants 






Of the 45 individuals who were invited to an intake session, two did not show up (illness (N=1); 
did not provide a reason (N=1)). Five participants did not meet in- and exclusion criteria (use 
of soft drugs (N=1); excess alcohol use (N=1); history of MDD (N=2); impaired vision (N=1). One 
eligible participant could not be included due to miscommunication among staff (no certified 
person available to administer treatment). One participant dropped out after the first lab visit 
for personal reasons unrelated to the project. Thirty-six participants completed the whole 
study (Figure 1). The analyses were conducted on 36 participants, except for the fMRI data 
for which 34 participants were included. fMRI data of two participants were excluded due to 
head motion (>3mm or 3° in any direction). Groups did not differ in age, IQ, sex distribution 





















Assessed for eligibility (N = 45) 
Excluded (N = 7) 
• Not meeting inclusion criteria  N = 5 
• Not attending the appointment N = 2 
Randomized (N = 38) 
Allocated to ARA290 group 
• Received:  18 
• Did not receive:  N = 1  
Allocated to Placebo group  
• Received:  19 
• Did not receive: N = 0 
• Drop-out N = 1  
(due to reasons unrelated to project) 
• No drop-out N = 0 
Lost to follow-up 
Analyzed 
Placebo group N = 18 
 
ARA290 group N = 18 
 Figure 1. Numbers of participants assessed and included in the data analysis of the double-blind, randomized 
placebo-controlled clinical trial.









Demographics and Characteristics  
     ARA290 (M±SD)   PLC (M±SD)  
Sex (f/m)    9/9   9/9  
Age      21.3 ± 3.5  20.5 ± 2.0 
IQ      104.4 ± 7.9  104.8 ± 7.8 
PANAS-S Positive  
Pre-treatment    31.5 ± 5.0  33.8 ± 6.0 
Post-treatment    31.4 ± 5.6  31.7 ± 6.3 
PANAS-S Negative  
Pre-treatment    12.6 ± 2.3  13.2 ± 2.6 
Post-treatment    12.7 ± 1.6  12.1 ± 1.8 
HADS Anxiety 
Pre-treatment     2.4 ± 1.8  4.0 ± 2.7 
Post-treatment    2.9 ± 1.3  4.0 ± 2.8 
HADS Depression 
Pre-treatment     1.4 ± 1.2  2.0 ± 2.0 
Post-treatment    2.2 ± 1.9  2.1 ± 2.2 
PLC = Placebo; f = female; M = Mean; SD = Standard Deviation 
 
Table 1. Demographics and Characteristics
Effects on affective symptoms and mood states
RM-ANOVA with Time (pre-post) as within-subject factor and Treatment (ARA290-Placebo) 
as between-subject factor was conducted separately on the Anxiety and Depression scale 
scores of the HADS. No main effects of Time were found in either analysis. A main effect of 
Treatment was found at trend level on the Anxiety scale (F(1, 34)=4.10,p=0.051), with lower 
anxiety levels in the ARA290 group (Table 1). No interactions effects were found. RM-ANOVAs 
on the Positive and Negative Affect scores revealed no main effect of Time, Treatment, or 
interaction effect (Table 1).  
 A 6x5x2 RM-ANOVA with Time (pre-treatment, day 1-5 post-treatment) and mood 
state (5 scales) as within-subject factors and Treatment (ARA290-Placebo) as between-
subject factor was conducted on 30 participants (ARA290, N=13; Placebo, N=17) because 
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eight participants had missing MSS scores on one or more days. A significant main effect 
of Scale (F(1.74,48.67)=142.19;p<0.01) and a trend-level interaction effect of Time x Scale 
(F(8.37,234.24)=1.85,p=0.066) were found. No main or interaction effects involving Treatment 
were found (Table S1). 
BOLD Response-Facial Expression Processing  
Whole brain- main effects of emotion. In both the ARA290 and Placebo group, the processing 
of fearful (Table S2a) and happy (Table S2b) facial expressions activated multiple regions 
within the occipital cortex, the precentral gyrus and motor cortex. No differences were found 
between the two groups for each of the emotions separately.
Whole brain- Intervention x Emotion interaction. A between groups difference on the 
contrast Fear > Happy was found in the lateral occipital cortex, supramarginal gyrus and 
temporal occipital fusiform cortex (Table 2; Figure 2). The mean z-scores of the clusters for 
each condition (happy and fear) are presented in Figure S1. The interaction of Intervention 
x Emotion in the fusiform gyrus is mainly driven by the difference in response of the ARA290 
and Placebo groups to happy faces. Specifically, processing of happy faces resulted in 
reduced activation in the ARA290 group compared to Placebo in the bilateral fusiform gyrus, 
whereas processing of fearful faces elicited increased activation in the right fusiform gyrus 
in the ARA290 group compared to placebo. A small volume correction applied within the 




















Figure 2. BOLD response during Facial Expression Processing task. Contrast Fear vs. Happy blocks, in clusters 
where BOLD response by ARA290 is greater than by placebo (x = 62 y = -68 z = -10) (z>2.0, corrected p<.05).










Contrast Fear > Happy for ARA290 > Placebo 
Region Hemisphere Cluster size 2 mm 
voxels 
Peak voxel coordinates 
(MNI) 
Z-value 
ARA290  > Placebo   X Y Z 





R 1461 12 -70 56 
   
 
3.20 
 L  -12 -70 56 
   
 
3.04 
Precuneus R  4 -80 54 
   
 
3.05 
Cuneus L  -6 -82 42 
   
 
2.92 
Fusiform gyrus R 1174 34 -52 -12 
   
 
3.25 
Lingual gyrus R  24 -62 -4 
   
 
3.13 
Cerebellum L  -2 -62 -28 
   
 
2.86 
Supramarginal gyrus R 1026 62 -36 16 
   
 
3.26 
Postcentral gyrus R  64 -14 28 
   
 
3.21 
Precentral gyrus R  62 6 18 





L 947 -44 -56 -8 
   
 
3.20 
Cerebellum L  -22 -60 -30 
   
 
2.88 
Fusiform gyrus L  -30 -72 -10 
   
 
2.62 







Behavioural response-Facial Expression Processing 
Groups did not differ in accuracy of gender discrimination during emotional face processing. 
Overall accuracy scores were high (95% correct) on both happy and fearful faces. A 2x2 RM-
ANOVA on reaction times with Emotion as within-subjects factor and Treatment as between-
subjects factor revealed no significant main or interaction effects. This allows us to asses any 
neural differences unconfounded by differences in performance of the task.
Effects on Emotional Test Battery
- Facial Expression Recognition  
RM-ANOVA was conducted with Emotion (six facial expressions) as within-subjects factor 
and Treatment (ARA290-Placebo) as between-subjects factor on total accuracy scores of 




A main effect of Treatment on total accuracy was found (F(1,34)=5.15,p=0.030) with 
reduced performance in the ARA290 group, but no significant interaction effect was found 
(F(3.27,111.41)=0.99,p=0.402) (Figure S2;Table S3). 
Separate RM-ANOVAs were conducted for each emotion of the FERT, with Intensity (10 levels) 
as within-subjects factor and Treatment (ARA290-Placebo) as between-subjects factor on 
accuracy scores. The main effect of Intensity was significant for each emotion. Differences 
between groups were only found on the emotions “Happy” and “Disgust”. A main effect of 
Treatment on the emotion “Happy” was found at trend level (F(1,34)=4.07,p=0.052), but no 
interaction effects were found. This was driven by worse relative performance in the ARA290 
compared to the placebo group. A main effect of Treatment (F(1,34)=5.10,p=0.031) and a 
trend-level Intensity x Treatment interaction (F(5,169.99)=2.13,p=0.065) were also found on 
the emotion “Disgust”. Overall, the emotion of “Disgust” was recognized less accurately by 
the ARA290 (M=24.4, SD=4.4) than the Placebo-treated group (M= 27.1, SD= 2.3). 
 Separate RM-ANOVAs were conducted with Emotion (6 levels) as within-subjects factor and 
Treatment (ARA290-Placebo) as  between-subjects factor on reaction times, target sensitivity 
(d’) and response bias (β) (Table S3). There were no effects of Treatment or interaction 
effects on the outcomes reaction times or target sensitivity. Only a main effect of Treatment 
on response bias (β) was found (F(1,34)=4.59,p=0.039), but no significant interaction effect 
(F(1.82,61.9)=0.90,p=0.40). Independent-samples t-tests revealed that the ARA290-treated 
group had a higher β value i.e. fewer false alarms (M=0.94, SD=0.070) than the Placebo-treated 
group (M=0.89, SD=0.08) for the sad faces (t(34)=2.11,p=0.043) (Table S3).  
- Emotion categorization 
A 2x2 RM-ANOVA on the reaction times, with Valence (Positive-Negative) as within-
subjects factor and Treatment (ARA290-Placebo) as between-subjects factor revealed a 
trend effect of Valence (F(1,34)=3.06,p=0.09) and a Valence x Treatment interaction effect 
(F(1,34)=5.61,p=0.024). This was driven by increased speed to positive (M=770, SD=134.9) vs 
negative (M=831, SD=156.8) words following ARA290 (t(17)= 3.50,p=0.003) (Table 3). There was 
no main effect of Treatment on reaction times (F(1,34)=0.261),p=0.613). The same analyses 
on the accuracy scores revealed no main or interaction effects (Table 3).  
- Emotional Memory -Free Recall 
A 2x2 RM-ANOVA on the recall scores with Valence (Positive-Negative) as within-subjects 
factor and Treatment (ARA290-Placebo) as between-subjects factor revealed no main or 
interaction effects (Table 3). The same analysis on Intrusive memory scores revealed only 
a main effect of Valence (F(1,34)=30.3,p<0.001). This was driven by increased false recalls 
(intrusions) in positive vs negative words in both groups (Table 3). 






- Emotional Memory -Recognition
A 2x2 RM-ANOVAs on Hits with Valence (Positive-Negative) as within-subjects factor and 
Treatment (ARA290-Placebo) as between-subjects factor revealed only a main effect of 
Valence (F(1,34)=36.50,p<0.001). This was driven by increased Hits in positive vs negative 
words in both groups (Table 3). 
The same analysis on reaction time (for hits) revealed only a main effect of Valence 
(F(1,34)=8.94,p=0.005). This effect was driven by longer reaction times to negative (M=1038.9, 
SD=254.6) vs positive (M=975.5, SD=252.1) words in the Placebo group (t(17)=2.75,p=0.014.
Separate RM-ANOVAs were conducted with Valence (Positive-Negative ) as within-subjects 
factor and Treatment (ARA290-Placebo) as  between-subjects factor on target sensitivity (d’) 
and response bias (β). These analyses revealed only a main effect of Valence on response 
bias. In both groups conservative response (i.e., a higher β value) was given to negative 
compared to positive words. 
Visual-Probe 
RM-ANOVA with Valence (Negative-Positive Bias Index) as within-subject factor and 
Treatment (ARA290-Placebo) as between-subject factors revealed no main effect of Valence 
(F(1,34)=2.89,p=0.098) or interaction effect. A main effect of Treatment (F(1,34)=6.82,p=0.013) 
was found. The ARA290 group had higher bias indexes for both valences (Figure 3). 

































































































































































































































































































































































































































































































































































































































































































































































































































































We used a cognitive neuropsychological model of antidepressant drug action to investigate 
antidepressant-like effects of ARA290, a derivative of EPO. Based on the literature on EPO, 
a single dose of ARA290 or placebo was administered to healthy volunteers and the effects 
were measured one week after administration. 
On the primary outcome measures, we observed two small trend-level differences between 
ARA290- and placebo-treated individuals. The recognition of both happy and disgusted 
facial expressions in the behavioural task tended to be lower after ARA290 than after 
placebo. ARA290 had no effect on the neural processing of facial stimuli (positive vs negative 
expressions) in the amygdala, hippocampus or vmPFC in healthy individuals. However, 
ARA290-treated individuals did show reduced neural responses to happy vs fearful faces in 
the fusiform gyrus, a region involved in face- specific processing (McCarthy et al., 1997).
On secondary outcomes, we found faster categorization of positive (self-referential) words 
compared to negative words in the ARA290-treated group, but not a better memory for 
positive words. Furthermore, ARA290-treated individuals had a higher positive attentional 
bias score than placebo-treated individuals. 
Unlike EPO (Miskowiak et al., 2007b), ARA290 did not increase memory-relevant neural 
response in the hippocampus during a picture recognition task. Finally, ARA290 did not have 
an effect on self-reported mood states or affective symptoms.
We hypothesized that ARA290 would be associated with reduced recognition of fearful and/
or increased recognition of  happy facial expressions. The observed trend-level effects on 
happy and disgust expressions were both in the same direction, which cannot be interpreted 
as an antidepressant-like effect. The reduced neural response to happy faces in the fusiform 
gyrus found in the ARA290 group, is the same region as reported by Miskowiak et al. (2007a) 
for EPO. However the direction of this effect was opposite: in Miskowiak et al. (2007a), EPO 
reduced the response to fearful vs neutral faces. In our study the difference was mainly driven 
by the effect of ARA290 on the happy faces which resulted in lower activation in the ARA290 
group in the bilateral fusiform gyrus. Processing of fearful faces elicited increased activation 
in the right fusiform gyrus in the ARA290 group compared to placebo.
In contrast with the previous demonstration of enhanced bilateral hippocampus response in 
healthy participants after EPO (Miskowiak et al., 2007b), ARA290 did not reliably increase the 
neural response in the hippocampi during the same picture recognition task. A methodological 
difference between the current study and the EPO study is that our participants completed 
the encoding task outside the scanner, meaning that the encoding task was completed one 
hour before recognition. The longer time frame between the two related tasks may have 
weakened the hippocampus response.






Consistent with a possible anti-depressant effect, ARA290 was associated with faster 
categorization of positive vs negative self-referential words. This is in line with the effects 
of single dosages of conventional antidepressants in healthy individuals (Harmer et al., 
2003; 2004) and could suggest that ARA290 may lead to a shift from negative towards more 
positive information processing, particularly regarding self- image. However, ARA290 had no 
effect on memory (i.e., recall and recognition) of positive vs negative self-referential words. 
Although there are no EPO studies with this specific outcome, we would expect improvement 
in memory for positive vs negative words, based on studies conducted with conventional 
antidepressant drugs (Harmer et al., 2004; Arnone et al., 2009). ARA290 did increase the 
attention for positive stimuli similar to the effect of citalopram on attention in healthy 
volunteers (Browning et al., 2007; Murphy et al., 2009). 
Taken together, on our primary outcomes we found that ARA290 tended to lower the 
recognition of both positive (happy) and negative (disgust) faces. ARA290 also elicited a 
differential neural response compared to placebo during processing of facial expressions, 
though in an unexpected direction. However, on the secondary outcomes  of emotional 
categorization and attention ARA290 did show antidepressant-like effects. Our findings 
show that while ARA290 modulates some aspects of emotional processing the direction 
and the strength of its effects is overall not congruent with the biomarker model of early 
antidepressant effects (Harmer et al., 2009, 2010), in which antidepressants produce a 
marked shift from a negative towards a positive emotional processing bias.
A strength of our study is that we had a relatively large sample size. Therefore, there is little 
risk that the present negative findings are due to type II error. However, the study has some 
limitations which need to be addressed. Except for measures related to mood, affective 
symptoms, we did not include baseline measurements prior to ARA290 administration. The 
reason for this is that all other measures include emotional stimuli which are subjective 
to learning and habituation effects. Therefore, all measurements related to emotional 
processing were completed one week after administration of ARA290 or placebo. Since we 
had to limit the baseline measurements we cannot be certain whether the several small 
effects found in this study are due to a pre-existing difference between the groups (i.e., 
randomization failure) or due to the ARA290 treatment. However, we did control for changes 
in mood and subjective states and participants were matched for age, sex and IQ.  
We based our current study design on findings with EPO (Miskowiak et al., 2007a; 2007b), 
as data published on ARA290 in healthy populations is still sparse. Therefore, we might not 
have been able to examine the effect of ARA290 with the highest effective dose and the time 
point on which ARA290 is the most effective. Administration of this dose (2 mg i.v.) to somatic 
patients (i.e., neuropathic pain patients) raised no safety concerns (Heij et al., 2012; Niesters 
et al., 2013). Since this is the first study assessing the antidepressant properties of ARA290 in 
humans, a single dose of 2 mg might have been too low to exert an antidepressant-like effect 
in healthy participants and/or the effect of ARA290 may have lasted shorter than one week.
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ARA290 acts on the receptor that initiates tissue-protective and anti-inflammatory actions. 
ARA290 might exert its beneficial effects on mood and cognition by decreasing inflammation 
in the central nervous system, and therefore it may be interesting to look at the effect of 
ARA290 in a subtype of depression, namely depressive patients with high inflammation 
biomarkers in their blood. 
As a first step towards a clinical trial in patients, we tested the effects of a single dose in 
healthy volunteers on the cognitive and neural processing of emotions one week after 
ARA290 administration. The model we have used has been validated with various registered 
antidepressants (reviewed by Harmer et al., 2009).  Although ARA290 does not seem to cause 
a marked shift from negative to positive emotional processing, it does have an effect on 
emotional processing in general. Our study needs replication and future studies may benefit 
from: a) higher doses and/or repeated administration of ARA290; and b) earlier measurement 
of the effects of ARA290 after its administration.
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Picture Encoding and Recognition Task: The picture encoding task was completed before 
scanning in a quiet room. One hour later participants completed the picture recognition 
task inside the scanner. The encoding and recognition tasks were selected because of 
hippocampal engagement in encoding and recognition of complex visual scenes (Stern et 
al., 1996; Hariri et al., 2003), and were the same as the ones used by Miskowiak et al. (2007b). 
Pictures were matched for emotional valence, arousal, and visual complexity, and were 
presented in a blocked paradigm to maximize sensitivity for hippocampal blood oxygenation 
level dependent (BOLD) signal change (Birn et al., 2002; Miskowiak et al., 2007b). In both 
tasks, each of the eight picture blocks (24 sec.) were preceded by brief instructions (2 sec.) 
and presented interleaved with 20 sec. of fixation cross, resulting in a total task duration of 
6 min. Blocks consisted of 6 pictures presented serially for 3 sec. interleaved with a 1 sec. 
fixation cross. The encoding and recognition tasks contained an equal number of pictures 
representing indoor and outdoor scenes. In addition, the recognition task contained an 
equal number of old (i.e., previously encoded) and new pictures. During encoding, volunteers 
determined whether the picture represented an “indoor” or “outdoor” scene, while in the 
subsequent recognition task they needed to determine whether the picture was “old” or 
“new”.
Visual Stimulation Condition: To explore whether drug-related effects observed during the 
Facial Expression Processing and Picture Recognition tasks were attributable to global effects 
of ARA290 on the BOLD signal, a control visual stimulation condition was used. A flashing 
checkerboard (frequency, 8 Hz) was presented in blocks of 15 sec. alternating with 15 sec. of 
a fixation cross for a total of 10 cycles (total duration of 5 min.). Participants were instructed 
to passively view the screen.
fMRI data analysis 
Picture Recognition Task: One explanatory variable (EV) was included in a general linear 
model, representing the recognition blocks during which participants had to respond 
whether they had seen the picture before or not. Contrasts were made for task-related 
activation and deactivation. 
Visual Stimulation Condition: One explanatory variable (EV) was included in a general linear 
model, representing the visual stimulation block during which participants had to view the 
flickering checkerboard.  One contrast of interest was made for task-related activation.






The first-level images of the contrasts of parameter estimates and their corresponding 
variances were registered to standard space and fed into a second level mixed effects group 
analysis (Woolrich et al., 2004). We tested for group main effects (one-sample t-tests) and 
between group effects (independent t-tests). The resulting statistic images were cluster 
corrected for multiple comparisons using an initial cluster forming threshold of z>2.0, and a 
corrected cluster significance of p<.05. 
Region of interest (ROI) analysis
The bilateral hippocampus was selected for the Picture Recognition Task, and area V1 for 
the Visual Stimulation Condition. To define the hippocampus ROI’s the Harvard-Oxford 
Subcortical Probability atlas was used, for area V1 the Juelich Histological atlas. All regions 
were thresholded at a 50% probability, binarized, and used as pre-threshold masks in the 
respective group level mixed effects analyses. Cluster correction was also used within the 





BOLD Response- Picture Recognition Task
Whole brain - main effect of task. In the ARA290 group, recognition of in- or outdoor scenes 
activated the visual cortex and a cluster in the paracingulate gyrus and supplementary motor 
cortex (Table S4). A similar pattern of activation was observed in the Placebo group (Table 
S4). The ARA290 group did not differ from the Placebo group in neural response during 
recognition of pictures, neither when the analysis was reduced to the ROI comprising voxels 
within the bilateral hippocampus. 
Behavioural Response- Picture Recognition Task
Picture Encoding:
Independent-samples t- tests revealed no significant differences between the ARA290-treated 
group (M = 44, SD = 10.8) and the Placebo-treated group (M = 47, SD = 1.9) on accuracy (t (33) 
= -1.084, p = 0.29). The same analysis revealed no differences between the ARA290-treated 
group (M = 762, SD = 157.5) and the Placebo-treated group (M = 784, SD = 157.9) on reaction 
times (t (33) = -0.418, p = 0.68).
Picture Recognition: 
Independent-samples t- tests on the four categories (misses, false alarms, correct rejections 
and hits) with Treatment as grouping variable revealed no differences between the two 
groups. Independent-samples t- tests on Target sensitivity (d’) and Response bias (β) with 
Treatment as grouping variable revealed a trend for response bias (p = 0.058). There was a 
trend toward a higher β value i.e. fewer false alarms in ARA290-treated (M = 0.13, SD = 0.15) vs 
Placebo-treated group (M = 0.04, SD, = 0.13) (t (34) = 1.963, p = 0.058).
BOLD Response- Visual Stimulation Condition
Both the whole brain and ROI analysis (within area V1) revealed no differences between the 
two groups in response to the visual stimulation condition.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 BOLD response during fear blocks - ARA290 and placebo groups 
Region Hemisphere Cluster size 2 mm 
voxels 
Peak voxel coordinates 
(MNI) 
Z-value 
ARA290   X  Y Z 
   
 
 
Occipital pole L 31647 -14 -100 -4 





R  42 -78 -14 
   
 
6.07 
Fusiform gyrus R  38 -54 -26 
   
 
5.88 
Lingual gyrus  R  8 -76 -16 
   
 
5.62 
Postcentral gyrus L 6314 -40 -26 56 
   
 
6.35 
Precentral gyrus L  -38 -8 64 







1527 -4 2 52 
   
 
5.04 
 R  10 4 46 
 





L  -10 18 30 
   
 
2.33 
Superior frontal gyrus R  8 14 54 
   
 
2.25 
Placebo     
Supplementary motor 
cortex 
L 41478 -8 8 50 
   
 
5.96 
Cerebellum R  24 -52 -24 
   
 
5.64 
Occipital pole R  22 -100 -4 
   
 
5.28 
Fusiform gyrus R  38 -58 -18 
   
 
5.22 
Inferior frontal gyrus R  50 12 6 
   
 
5.03 
Precentral gyrus L  -38 -20 68 
   
 
4.80 
z>2.0 and a corrected cluster significance threshold of p=0.05 
 
Table S2A BOLD response during fear blocks - ARA290 and placebo groups




BOLD response during happy blocks - ARA290 and Placebo groups 
Region Hemisphere Cluster size 2 mm 
voxels 
Peak voxel coordinates 
(MNI) 
Z-value 
ARA290   X  Y Z 
   
 
 
Fusiform gyrus  L 33197 -34 -78 -16 
   
 
6.25 
 R  36 -60 -22 





R  42 -76 -14 
   
 
6.20 
Occipital pole  L  -20 -92 0 
   
 
5.80 
Cerebellum R  36 -52 -28 
   
 
5.68 
Precentral gyrus R 1999 46 -2  46 
   
 
4.68 
Placebo      
   
 
 
Cerebellum R  53450 26 -52 -24 





R  38 -76 -20 
   
 
5.36 
Occipital pole R  22 -100 -4 
   
 
5.30 
 L  -14 -100 -4 
   
 
5.26 
Fusiform gyrus R  38 -58 -20 





R  10 2 50 
   
 
5.18 
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TABLE S3 
Facial Expression Recognition Task 
 
    ARA290 (M ± SD) PLC (M ± SD)  
Accuracy (Hits) 
Anger     18.1 ± 5.1  20.6 ± 4.2   
Disgusted   24.4 ±  4.4  27.1 ±  2.3  
Fearful    24.9 ± 2.6  25.7 ±  2.8 
Happy     26.9 ±  3.8   29.2 ± 2.7  
Sad     17.0 ±  3.8  19.1 ±  7.6  
Neutral    3.9 ±  0.3 3.7 ±  0.7  
Reaction time (ms) 
Anger     1275.2 ± 299.5  1236.5 ± 297.8 
Disgusted   1028.9 ± 433.5   991.9 ± 219.2 
Fearful    1016.1 ± 309.4  1133.1 ± 317.2 
Happy     866.1 ± 250.4   810.6 ± 198.0 
Sad     1154.0 ± 239.6  1148.5 ± 391.3 
Neutral    788.0 ± 387.3  882.3 ± 393.0 
Target sensitivity (d’)  
Anger     0.84 ± 0.04  0.87 ± 0.03 
Disgusted   0.88 ± 0.05  0.91 ± 0.02 
Fearful    0.89 ± 0.02  0.90 ± 0.02 
Happy     0.92 ± 0.02  0.93 ± 0.02 
Sad     0.85 ± 0.02  0.86 ± 0.05 
Neutral    0.90 ± 0.04  0.88 ± 0.07 
Response Bias (β) 
Anger     0.83 ± 0.15  0.90 ± 0.10 
Disgusted   0.71 ± 0.21  0.78 ± 0.15 
Fearful    0.75 ± 0.13  0.83 ± 0.15 
Happy     0.96 ± 0.06  0.98 ± 0.04 
Sad     0.94 ± 0.07*  0.89 ± 0.08 
Neutral    -0.89 ± 0.31  -0.76 ± 0.46 
PLC = Placebo, M = Mean; SD = Standard Deviation 
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Main Effects Picture Recognition task (activation) 
Region Hemisphere Cluster size 2 mm 
voxels 
Peak voxel coordinates 
(MNI) 
Z-value 
ARA290   X  Y Z 
   
 
 
Lingual gyrus L 60522 -4 -88 -8 




fusiform cortex  
R  28 -54 -10 
   
 
7.32 
Occipital pole L    -26 -90 6 





R    26 -86 16 






R    30 -84 14 
   
 
6.94 
Paraci gulate gyrus L 2975 -6 12 46 
   
 
6.50 
 R  2 22 44 





L  -6 4 52 
   
 
5.74 
Placebo     
Parahippocampal 
gyrus 
L 74570 -22 -40 -16 





R    30 -48 -12 
   
 
6.85 
Occipital pole L  
  
 
-8 -94 -8 
   
 
6.75 
 R  20 -98     6 
   
 
6.53 
Lingual gyrus L  -20 -48 -12 
   
 
6.64 
z>2.0 and a corrected cluster significance threshold of p=0.05 
 
 





































































































Figure S1. Mean z-stats (SE) for Fear and Happy conditions separately of the clusters resulting from contrast 
Fear > Happy (ARA = ARA290; PLC = Placebo).









































Facial Expression Recognition 
ARA290
Placebo
Anger Disgust Fear Happy Sad 
 Figure S2. Accuracy scores (SE) on the Facial Expression Recognition task.








The Effects of ARA290, an Erythropoietin Analogue, 
on Resting State Networks Associated with Depression: 
a randomized placebo-controlled trial. 
H Cerit, E Ghariq , KG Ramlakhan, IM Veer, 





Studies on the cognitive and neural effects of Erythropoietin (EPO) indicate that EPO 
may have antidepressant effects. ARA290 is an EPO-analogue peptide without dangerous 
hematopoietic side-effects, but it may still have neurotrophic and antidepressant effects.  In 
a previous report, we found that ARA290 may modulate some aspects of cognitive and neural 
processing. The first aim of this study was to investigate whether ARA290 affects connectivity 
in the brain, in relation to eight standard networks. The primary networks of interest were the 
default mode network (DMN) and the executive salience network, known to be involved in 
MDD. The second aim of this study was to investigate whether ARA290 affects connectivity of 
the hippocampus, amygdala and/or the fusiform gyrus with other brain regions.
Healthy participants (N=36) received ARA290 (2 mg) or placebo in a double-blind, randomized, 
parallel-group design. Effects on functional connectivity (resting-state fMRI) were assessed 
one week after administration. Whole brain analysis revealed that ARA290 did not affect 
connectivity in relation to the eight standard networks, nor in relation to the seed regions 
(hippocampus/amygdala and fusiform gyrus) in the current sample of healthy volunteers.
We did not find evidence for an effect of ARA290 on MDD related networks, and thus could 
not confirm our hypothesis that the effects of ARA290 on functional connectivity contribute 
to its putative antidepressant effects. Future studies may benefit from higher dosage of 
ARA290 administration, a shorter time lag between administration and measurements, and 
a crossover design.







The need for new pharmacological treatment options for depression has led to development 
of compounds that target different molecular pathways. One such compound is Erythropoietin 
(EPO), a glycoprotein that regulates erythropoiesis. EPO also crosses the blood brain barrier 
(BBB) and has neuroprotective and neurotrophic effects when delivered in high doses (Brines 
et al., 2000; Shingo et al., 2001; Gonzalez et al., 2009). Studies have found beneficial effects of 
EPO on cognitive functions in patients with schizophrenia (Ehrenreich et al., 2007a), multiple 
sclerosis (Ehrenreich et al., 2007b) and depression (Miskowiak et al., 2010). 
The 11‐amino acid, linear peptide ARA290 is an EPO analogue and exerts tissue-protective 
effects but is not a hematopoietic stimulant (Brines et al., 2008). ARA290 exerts anti-
inflammatory actions by acting on the innate repair receptor (IRR) (Niesters et al., 2013). 
Specifically, activation of the IRR initiates multiple signalling pathways initiating tissue-
protective actions, one of which is the inhibition of inflammation-induced apoptosis (Brines 
& Cerami 2012). More importantly, ARA290 does not stimulate erythropoiesis and does not 
initiate hematopoietic actions, even not after repeated administration (van Velzen et al., 
2014).
Given the beneficial effect of ARA290 on cell survival and tissue-protection and the absence 
of dangerous side effects, we investigated the potential antidepressant effects of ARA290 
in a clinical trial in healthy volunteers (Cerit et al., under review), using the neurocognitive 
model (Harmer et al., 2009). This trial was modelled after the EPO studies and the effects of 
treatment were assessed one week after ARA290 administration. Some small effects were 
observed on attentional bias and on the BOLD response to emotional information, but not 
on the primary outcome measures. Furthermore, ARA290 elicited a larger BOLD response to 
fearful vs happy faces in the fusiform gyrus. This is one of the same regions that were sensitive 
to EPO administration (Miskowiak et al., 2007a); however, this latter effect was not in the 
expected direction (Cerit et al., under review).
Altered resting state-state connectivity is also suggested to contribute to the pathophysiology 
of MDD. Several pharmacological studies have investigated the effect of conventional 
antidepressant drugs on connectivity within the affective networks associated with MDD 
(Anand et al., 2005; McCabe and Mishor, 2011; van Wingen et al., 2014). These studies have 
mainly focussed on abnormalities in the cortico-limbic mood regulating circuit (MRC), 
the default-mode network (DMN) and the task-positive network (TPN) as these have been 
reported to be altered in depressed patients (see review by Wang et al., 2012). Seven days 
of either citalopram, reboxetine or placebo was administered to healthy volunteers and a 
seed based connectivity analysis was conducted. Both citalopram and reboxetine reduced 
connectivity within the cortico-limbic network (McCabe and Mishor 2011). Two weeks 
of duloxetine administration in healthy volunteers resulted in reduced DMN and TPN 
connectivity (van Wingen et al., 2014). 
CHAPTER 3
62
In order to gain a comprehensive understanding of the potential of ARA290 as an 
antidepressant, we investigated both its effects on cognitive and neural processing of 
emotional information (Cerit et al., under review) and its effect on resting-state connectivity. 
This allows us to investigate whether the effects of ARA290 described in the previous report 
(Cerit et al., under review) are task specific or rather a general effect of ARA290 on these 
regions. In summary, in the present study we examined the effect of ARA290 on resting state 
connectivity in the same healthy volunteers as in our previous report (Cerit et al., under 
review). We employed a dual regression and a seed-based dual regression analysis using seed 
regions, known to be differentially activated in response to (emotional) stimuli following EPO 
and/or ARA290 administration compared to placebo (Miskowiak et al., 2007a, 2007b, 2010; 
Cerit et al., under review). Specifically, the following seeds were identified and compared 
over the groups: left and right hippocampus, left and right hippocampus-amygdala complex 
and bilateral fusiform gyrus. The following hypotheses were tested: 
a) ARA290 affects connectivity in the brain (in relation to eight standard networks (Beckmann 
et al., 2005), together covering around 80% of the brain) and specifically the default mode 
network (DMN) and the executive salience network, known to be involved in MDD.
b) ARA290 affects connectivity of the hippocampus, amygdala and/or the fusiform gyrus 
with other brain regions.








The data were acquired in the same participants as in a previous report, in which detailed 
information about the participants is outlined (Cerit et al., under review). A total of 36 
participants (18-35 years) were recruited and randomly assigned to either placebo or ARA290 
condition. The groups did not differ in age, IQ, sex distribution and clinical characteristics 
(Cerit et al., under review). 
Design
We used a randomized, double-blind placebo-controlled, parallel-group design. 
Randomization was carried out in blocks of six, and was stratified for sex. The study was 
conducted at the LUMC and randomization was carried out by the LUMC pharmacy, Leiden. 
The study included two lab visits separated by 6 or 7 days. Participants came into the lab 
twice and were administered either placebo or ARA290 (2mg) on the first lab visit. During the 
second visit, which took place one week later, all participants underwent (functional) MRI 
(fMRI) scanning, both task-related (Cerit et al., under review) and resting state fMRI scanning; 
both scans were part of one study and were acquired in one scanning session and in the 
same sample as reported in Cerit and colleagues (under review).  
Image acquisition
Imaging data were acquired on a Philips 3.0-Tesla Achieva MRI scanner using a 32-channel 
SENSE head coil for radiofrequency transmission and reception (Philips Healthcare, Best, The 
Netherlands). RS-fMRI data were acquired using T2*-weighted gradient-echo echo-planar 
imaging with the following scan parameters: 200 whole-brain volumes; repetition time (TR) 
= 2.2 sec; echo time (TE)= 30 ms; flip angle= 80°; 38 axial slices scanned in ascending order; 
FOV = 220 x 220 mm; voxel size 2.75 x 2.75 x 2.75 mm, plus 10% interslice gap. For registration 
purposes and normalization to standard space, a high-resolution anatomical image (T1-
weighted ultra-fast gradient-echo acquisition; TR=9.76 ms; TE= 4.59 ms; flip angle= 8°; 140 
axial slices; FOV= 224 x 177.33 mm; in plane voxel resolution = 0.875 mm x 0.875 mm; slice 
thickness= 1.2 mm) and a high-resolution T2*- weighted gradient-echo EPI scan (TR= 2.2 sec; 
TE= 30 ms; flip angle=80°; 84 axial slices; FOV= 220 x 220 mm; in plane voxel resolution= 1.96 
x 1.96 mm, slice thickness= 2 mm) were acquired for each participant. In accordance with 
the Leiden University Medical Center’s policy, all anatomical MRI scans were screened by a 




Before statistical analysis, all MRI scans were submitted to a visual quality control check to 
ensure that no gross artefacts were present in the data. Data analysis was performed with 
Functional Magnetic Resonance Imaging of the Brain Software Library (FSL version 5.0.1, 
Oxford, United Kingdom, www.fmrib.ox.ac.uk/fslSmith et al., 2004). Anatomical locations 
were determined using the Harvard-Oxford cortical and subcortical structures atlas 
integrated in FSL. 
Resting-State functional connectivity analysis
Pre-processing of RS-fMRI images was carried out using FEAT (FMRI Expert Analysis Tool) 
Version 5.98, part of FSL. The following processing steps were applied: motion correction 
(Jenkinson et al., 2002), brain extraction (Smith, 2002), spatial smoothing using a Gaussian 
kernel with a full width at a half maximum (FWHM) of 6 mm, grand-mean intensity 
normalization of the entire 4D dataset by a single multiplicative factor and a high-pass 
temporal filtering equivalent to 100 sec. Time series statistical analysis was carried out with 
local autocorrelation correction (Woolrich et al., 2001). After pre-processing, the functional 
images were registered to the corresponding high-resolution echo planar images, which were 
registered to the T1-weighted images, which in turn were registered to the 2 mm isotropic 
MNI-152 standard space images (T1 standard brain averaged over 152 subjects; Montreal 
Neurological Institute, Montreal, QC, Canada; Jenkinson and Smith, 2001; Jenkinson et al., 
2002). The registration parameters were combined to obtain the registration matrix from 
native space to MNI space and its inverse (from MNI space to native space).
The functional connectivity analysis was performed using the dual regression method of 
FSL, a technique that allows a voxel-wise comparison of resting-state functional connectivity 
(previously described in Filippini et al., 2009). First, we performed a model-free analysis of 
eight standard resting state networks (Beckmann et al., 2005), representing 80% of the total 
brain volume (Khalili-Mahani et al., 2012). Previously, localized and drug-specific changes in 
functional brain connectivity have been shown using these networks in resting-state fMRI 
studies (Cole et al., 2013; Khalili-Mahani et al., 2012; Klumpers et al., 2012; Niesters et al., 
2012). Secondly, we analysed the resting state connectivity changes induced by ARA290 in 
relation to two seeds, namely the amygdala-hippocampus complex (Miskowiak et al., 2010), 
determined using the Harvard-Oxford cortical and subcortical structures atlas integrated in 
FSL, and the fusiform gyrus (functional seed, determined by the contrast: Fearful vs Happy in 
a previous report Cerit et al., under review and in line with Miskowiak et al., 2007a).
In both analyses we used a dual regression analysis to create subject specific statistical maps: 
voxel-wise Z-scores of functional connectivity to each of the eight networks or to the seed 
regions. We accounted for non-specific and physiological variations by including nuisance 
variables, corresponding to fluctuations in the deep white matter and cerebrospinal fluid 






(Birn, 2012). The statistical maps were then used for voxel-wise inference testing of the effect 
of ARA290 on functional connectivity with each of these networks or seed regions, using a 
General Linear Model (GLM) approach as implemented in FSL. Two statistical contrasts 
were made with regard to changes in functional connectivity between the two groups: 
ARA290>placebo and placebo>ARA290. Voxel-wise nonparametric permutation testing was 
performed using FSL-randomise (5000 permutations; Nichols and Holmes, 2001). All statistical 
maps were Family-Wise Error (FWE) corrected using p < 0.05, based on the Threshold-Free 
Cluster Enhancement (TFCE) statistic image (Smith and Nichols, 2009), applying a minimum 
cluster size of 80 mm3.
Results
Voxel-wise comparison of each group of participants separately versus the eight predefined 
general resting-state networks (Beckmann et al., 2005), using dual regression, revealed that 
the eight networks were significantly present in both groups of participants (Fig. 1). Figure 1 
seems to show some differences between the two groups, for instance the contribution of the 
cingulate cortex to the auditory and somatosensory system (network c in Fig.1) in the placebo 
group is not significantly present in the ARA290 group. However, when directly comparing the 
two groups of participants, no significant differences in functional connectivity in any of the 
eight networks were found (p<0.05, threshold-free cluster enhancement corrected). Thus, the 
apparent difference between the groups in cingulate cortex contribution to network c (Fig. 
1) did not reach significance (it was present in the uncorrected data p<0.05). Similarly, when 
comparing the two groups of participants, we did not find significant differences in functional 

























a)      x = 17            y = -73                           z = -12 b)      x = -13             y = -61                                z= 6 
c)       x = 3   y = -17 z= -1.5            y = -21                z = 51 d)       x = 1 
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g)       x = 45            y = - 42                z = 47 
f)       x = 5                y = 6                                      z = 27 
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Figure 1. Statistical connectivity maps (P < 0.05, threshold-free cluster enhancement corrected) of the resting-
state network connectivity in relation to eight template networks (Beckmann et al., 2005): medial and lateral 
visual systems (networks a and b respectively), auditory and somatosensory system (network c), sensorimotor 
system (network d), the default mode network (network e), executive salience network (network f) and visual-
spatial and working memory networks (networks g and h), separately for the placebo-group (at the top) and for 
the ARA290-group (at the bottom).







The present study examined the effect of ARA290, an EPO analogue, on resting state 
connectivity in healthy volunteers using a randomized, double-blind, placebo-controlled, 
parallel group design. We did not find evidence that ARA290 affects functional connectivity. 
Specifically, ARA290 did not affect functional connectivity with brain regions that showed 
effects in the EPO studies, nor with the networks typically affected by antidepressants. Our 
results indicate that the differential BOLD response of the bilateral fusiform gyrus in response 
to fearful vs happy faces after ARA290 administration (Cerit et al., under review), is due to 
task specific activation rather than a general function of the fusiform gyrus as part of a 
coherent network. The other seeds included the hippocampus and hippocampus-amygdala 
complex and were based on ROIs which were found to be differentially activated after EPO 
administration. Although ARA290 did not have an effect on the hippocampus (or amygdala) 
during task related BOLD response (Cerit et al., under review), these seeds were of interest 
since ARA290 was expected to elicit similar effects as EPO (Miskowiak et al., 2007b; 2010). 
Overall, our findings indicate that the currently used dosage of ARA290 does not seem to 
exert antidepressant-like effects on resting state connectivity.
A strength of our study is that we had a relatively large sample size and power. Furthermore, 
participants were matched for age, sex and IQ. We conducted a model-free analysis of eight 
standard resting state networks (Beckmann et al., 2005) which encompasses approx. 80% of 
the total brain volume (Khalili-Mahani et al., 2012) and, therefore, ensures an thoroughgoing 
assessment of the possible effects of ARA290 on functional connectivity. However, this study 
has some limitations which need to be addressed.
We did not apply retrospective correction on our data in order to exclude the noise originating 
from physiological confounders (e.g., heartbeat, breathing related chest movement, 
respiration rates). Since physiological noise influences fluctuations in the MRI signal and as 
a consequence the estimates of functional connectivity (Birn, 2012), it is conceivable that a 
possible effect of ARA290 has been drown out by physiological noise.
The lack of effect may have been due to several reasons which may need attention in future 
studies investigating the effect of ARA290 on resting state connectivity. Since this is the first 
study assessing the antidepressant properties of ARA290 in humans, selecting the right dose 
and treatment duration was based on previous studies with pain patients. A single dose of 
2 mg might have been too low to exert an antidepressant-like effect in healthy participants 
and/or the effect of ARA290 may have lasted shorter than one week. We might not have been 
able to examine the effect of ARA290 with the highest effective dose and the time point on 
which ARA290 is the most effective. Administration of this dose (2 mg i.v.) to somatic patients 




Within this context some pharmacological differences should also be mentioned. EPO 
was administered as 40 000 IU (equal to 336 micrograms) and has a half-life of approx. 5 
hours (Miskowiak et al., 2007a; Eckardt et al., 1989; McMahon et al., 1990) whereas, ARA290 
was administered as 2000 micrograms to healthy volunteers and has a plasma half-life of 
2 minutes (Niesters et al., 2013). Once the IRR receptor is activated by ARA290 it initiates 
multiple signalling pathways resulting in tissue protective and anti-inflammatory actions. It 
is possible though that these effects are not enduring as the effects of EPO, since ARA290 and 
EPO differ in half-life and the exact signalling pathways they activate. 
The antidepressant effects of six week sertraline treatment  in MDD patients increased 
corticolimbic connectivity compared to baseline (at which the connectivity was reduced) 
(Anand et al., 2005), therefore, it is conceivable that the effect of ARA290 may not have been 
detected due to its assessment in healthy volunteers i.e., in order to detect an antidepressant 
effect on connectivity associated with affective networks one may need to asses these specific 
effects in a patient group. On the other hand, administration of conventional antidepressant 
drug for a period of one to two weeks in healthy volunteers did elicit an difference between 
intervention and placebo groups as reduced connectivity in healthy volunteers was reported 
(McCabe and Mishor 2011; van Wingen et al., 2014). Similar to pharmacological resting-
state studies carried out with antidepressant drugs (i.e. including daily administration for 
at least one week), future resting-state studies with ARA290 may also benefit from repetitive 
administration (Anand et al., 2005; McCabe and Mishor, 2011; van Wingen et al., 2014) and 
from a baseline assessment in order to exclude intersubject variability (Anand et al., 2005).  
The fMRI study with ARA290 administration in the same healthy population yielded modest 
to small effects on neural and behavioural measures of emotional processing which was 
measured by means of the neurophysiological model of drug action (Cerit et al., under 
review). The finding that ARA290 does not affect functional connectivity in the same healthy 
population does strengthen the possibility that the effect of ARA290 on task related activity 
was not affected by randomization failure. Although the neuropsychological model of drug 
action is validated and assesses depression related emotional processes both at neural as well 
as behavioural level, the emerging view is that instead of different brain regions activated in 
response to stimuli, alterations in specific neural circuits may underlie depressive symptoms 
(Wang et al., 2012). Our finding of ARA290 not eliciting an effect on depression related 
networks may be interpreted as ARA290 lacking the strength to affect functional connectivity 
in a way that could contribute to observable/detectable antidepressant effects. Nonetheless, 
a future resting-state study would benefit from designs used in previous pharmacological 
resting state studies including baseline measurements (Anand et al., 2005), administration 
of treatment for at least one week and a crossover design (van Wingen et al., 2014). This may 
provide us with a better understanding of the effects of ARA290 on functional connectivity in 
healthy volunteers.
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The Effect of Tryptophan on the Cortisol Response to Social 
Stress Is Modulated by the 5-HTTLPR genotype 
H Cerit, LAW Jans, AJW Van der Does




Objective: The S’/S’ (S/S, S/Lg and Lg/Lg) variant of the serotonin (5-HT) transporter gene 
linked polymorphic region (5-HTTLPR) is associated with less efficient neurotransmission 
and may be more reactive to 5-HT manipulations. We tested the effects of l-tryptophan 
supplements on the cortisol response induced by a social stressor in S’/S’ and L’/L’ (La/La) 
carriers.
Methods: In a double-blind parallel design, 25 S’/S’ carriers and 21 L’/L’ carriers were 
randomized to take l-tryptophan (2.8 g/d) or placebo supplements for six days. At day 7 
participants were exposed to the Trier Social Stress Test. Salivary cortisol and subjective 
mood states were monitored before, during and after the stress procedure. 
Results: S’/S’ carriers who took l-tryptophan supplements had a significantly lower cortisol 
response to stress than S’/S’ carriers who took placebo. Tryptophan had no effect on cortisol 
in L’/L’ carriers and no effect on subjective mood states in either genotype group.
Conclusion: Tryptophan attenuates the cortisol response to acute social stress depending 
on 5-HTTLPR genotype. S’/S’ carriers may indeed be more reactive to 5-HT manipulations.







The serotonin (5-hydroxytryptamine; 5-HT) neurotransmission system and the hypothalamic-
pituitary-adrenal axis (HPA axis) have complex interrelationships (Porter et al., 2004). Both 
systems have important roles in the response to stress and are implicated in depression. 
In the present study, we examined the effect of the 5-HT precursor l-tryptophan (TRP) on 
reactivity of the HPA axis, specifically investigating whether this effect is modulated by 
genetic variation in the 5-HT system. 
The serotonin transporter (5-HTT) membrane protein is essential in regulating the 
concentration of 5-HT in the synaptic cleft. The 5-HTT is encoded by the SLC6A4 gene, and 
transcriptional activity of this gene is regulated by the 5-HTT-linked polymorphic region 
(5-HTTLPR). Two major variants of the 5-HTTLPR exist, with functional significance in that 
the short (S) allele of the 5-HTTLPR is associated with less transcriptional efficiency and less 
5-HTT expression than is the long (L) allele (Lesch et al., 1996). A functional A/G polymorphism 
(rs25531) has been found within the L allele (Nakamura et al., 2000) as well, indicating that 
the 5- HTTLPR is functionally triallelic (S / Lg / La). The Lg variant is associated with reduced 
5-HTT transcriptional efficiency, comparable to the S allele (Hu et al., 2006; Praschak-Rieder 
et al., 2007; Reimold et al., 2006). The reduced efficiency 5-HTT variants (S and Lg) are referred 
to as S’, the La variant as L’. Biallelic classifications are indicated as S and L. 
Several studies have found that differences in 5-HTTLPR genotype are associated with 
differing HPA axis reactivity in healthy individuals. Healthy girls (aged between 9 and 14 years) 
who were homozygous for the S allele showed an increase in cortisol response during and 
following exposure to a laboratory stress task, whereas girls carrying at least one copy of the 
L allele had a slight decrease in cortisol response (Gotlib et al., 2008). This differential pattern 
of cortisol response was independent from history of depression in participants’ mothers. 
Way and Taylor (2010) exposed healthy young adults to a similar social stress task and found 
that individuals homozygous for the S allele had a significantly stronger cortisol response 40 
minutes after onset of the stressor. The individuals homozygous for the L allele had the least 
response, with the heterozygous (S/L) falling in between.
Wüst et al. (2009), however, did not observe an effect of 5-HTTLPR on the cortisol response to 
a social stress task. This study had a large sample size (N = 216) and grouped individuals based 
on triallelic classification. The non-replication may have been caused by the fact that all 126 
female participants used oral contraceptives, which dampen the cortisol response to stress 
(Kirschbaum et al., 1999). Another recent study reported no effect of 5-HTTLPR genotype 
or neuroticism on the cortisol response to social stress in 94 college students (Verschoor & 
Markus, 2011). Mueller et al. (2011) even reported a larger cortisol response to social stress 
in both younger (18-31 years) and older (54-68 years) adults who were homozygous for the L’ 
allele than individuals carrying at least one S’ allele. This effect was not observed in children 
(8-12 years). In the younger adults (N = 106), genotype interacted with early (during the first 
five years of life) stressful life events: L’/L’ individuals had a much higher cortisol response to 
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stress than S’ carriers in the absence of early stressful life events. This pattern was reversed 
for people who had experienced three or more early life events. In a study with new-borns, 
S’/S’ individuals had a larger cortisol response to a pain stimulus (heel prick) (Mueller et al., 
2010). Finally, male S’/S’ carriers with a history of stressful life events had a larger cortisol 
response 35 minutes after the onset of the social stressor than male S’/S’ carriers without 
such history. The cortisol response in S’/S’ carriers with a history of stressful life events was 
also higher than that of male S’/L’ and L’/L’ carriers (with and without life events) (Alexander 
et al., 2009).  
The central theme of these reports demonstrates that 5-HT function and 5-HTTLPR genotype 
affect HPA axis reactivity to social stress; however, the direction of this interaction has yet to 
be conclusively established. Age as well as both type and time of occurrence of stressful life 
events have been suggested to play a role in the effect of gene-environment interactions on 
cortisol response (Mueller et al., 2011).   
The relationship between the 5-HT system and HPA axis reactivity has also been investigated 
by manipulating tryptophan (TRP) levels in stress-vulnerable populations, as defined by 
family or personal history of depression or by questionnaire scores indicating vulnerability, 
e.g. high neuroticism.  Experimental interventions that temporarily increase TRP include: 
carbohydrate rich/protein poor (CR/PP) meal (Markus et al., 1998; Markus et al., 2000b), 
tryptophan-rich egg protein hydrolysate (EPH) (Markus et al., 2010), carbohydrate rich drink 
(Markus, 2007), whey protein α-lactalbumin (α-lac) (Markus et al., 2000a; Merens et al., 2005; 
Booij et al., 2006; Nesic & Duka, 2008) and tryptophan-rich hydrolyzed protein (HP) (Firk & 
Markus, 2009). Stress responses were induced with the cold pressor test (CPT), arithmetic 
stress task (under noise stimulation) or public speaking. Stress-vulnerable populations 
were expected to benefit from increasing TRP availability, as expressed in improved mood 
and lower cortisol responses to stress. The above-mentioned interventions and stressors 
revealed no consistent pattern of effects. The lack of a consistent effect may have been due 
to methodological limitations, including: a relatively small impact of the interventions on 
tryptophan concentrations, less than optimal timing of the cortisol measurements, or the 
nature of the stressor. Non-social stressors (e.g. cold pressor) are less reliable in eliciting a 
cortisol response than are social stressors (e.g. public speaking) (Dickerson & Kemeny, 2004). 
A recent study combined a TRP manipulation and stress exposure with measurement of 
5-HTTLPR genotype (Markus & Firk, 2009). Sixteen healthy S’/S’ and 14 L’/L’ carriers were 
exposed to stress one hour after a single dose tryptophan (0.8 g) and after taking placebo 
in a cross-over design. The stress procedure consisted of a combination of backward 
counting tasks and cold-pressor exposures at unpredictable intervals. TRP improved mood 
and reduced backward counting errors in S’/S’ participants but not in L’/L’ participants, and 
no group differences were found on the cortisol response to stress. Remarkably, cortisol 
concentrations were lower at post-stress than at pre-stress regardless of intervention 
or genotype. The number of cortisol measurements was limited to single pre- and post-






stress samplings. The authors concluded that TRP challenge improves mood and stress 
performance in S’/S’ participants (Markus & Firk, 2009). ‘Stress performance’ referred to the 
number of errors in the backward counting task that was part of the stressor. Under placebo 
conditions, S’/S’ participants made more mistakes than L’/L’ participants, which seems to 
have been corrected by TRP. 
Given the methodological issues in previous TRP loading studies, we examined the effect of 
six days of TRP supplementation on reactivity of the HPA axis to a social stressor, specifically 
investigating whether its role is modulated by 5-HTTLPR genotype. We used a parallel 
design, exposing every participant to the stressor only once. Furthermore, we monitored 
physiological data for 95 minutes at six time points pre- and post-stress. Possible confounders 
of the stress response were avoided by excluding users of oral contraceptives and by testing 
female participants during the luteal phase of their menstrual cycle. We tested the following 
hypotheses: 1) S’/S’ carriers have larger cortisol responses to social stress than L’/L’ carriers; 





Participants were selected from a pool of 581 genotyped individuals who had been recruited 
at various sites at Leiden University and through local advertisements.  Participants were 
non-smokers and were included if all four grandparents were West-European. For the present 
study, the age range was 18 to 35 years and Body Mass Index was between 19 and 29 kg/m²). 
Exclusion criteria were a current diagnosis of depression or post-traumatic stress disorder, 
a lifetime history of psychosis, and use of medication, including oral contraceptives. The 
presence of anxiety disorders was also assessed, but this was not an exclusion criterion. The 
following two genotype groups S’/S’ (S/S, S/Lg and Lg/Lg variants) and L’/L’ (La/La variant) 
were invited to participate in the present study. Participants received a reward of € 40. The 
research was approved by the Ethics Committee of the Leiden University Medical Center in 
The Netherlands. 
Genotyping
Genetic Assessment. DNA was obtained using the Oragene Self-Collection Kit – DISC format 
(DNA Genotek Inc, Ottawa, ON, Canada); 200 μl of saliva was collected in lysis buffer (100 mM 
NaCl, 10 mM EDTA, 10 mM Tris pH 8, 0.1 mg/ml proteinase K and 0.5% w/v SDS) until further 
processing. Genomic DNA was isolated from the samples using the Chemagic buccal swab kit 
on a Chemagen Module I workstation (Chemagen Biopolymer-Technologie AG, Baesweiler, 
Germany). DNA concentrations were quantified by OD260 measurement and by agarose gel 
electrophoresis. The average yield was approximately 4 mg of genomic DNA per sample.
Polymerase chain reaction amplification 
The region of interest from the 5-HTT gene was amplified by triplex PCR using the following 
primers: a FAM-labeled primer HTTLPR-FWFAM 5’-TCCTCCGCTTTGGCGCCTCTTCC-3’, and 
a reverse primer HTTLPR-RV 5’-TGGGGGTTGCAGGGGAGATCCTG-3’. Typical PCR reactions 
contained between 10 and 100 ng genomic DNA template, 10 pmol of forward and 
reverse primer. PCR was carried out in the presence of 5% DMSO with 0.5U of BioThermAB 
polymerase (GeneCraft, Munster, Germany) in a total volume of 30 µl using the following 
cycling conditions: initial denaturation step of 5 min at 95oC, followed by 40 cycles of 30 sec 
96oC, 30 sec 61oC, 60 sec 72oC and a final extension step of 10 min 72oC. After PCR 5 µl of the 
sample was subjected to restriction digestion with the enzyme HpaII in a total volume of 20 
µl. Restriction enzyme mix was incubated with DNA for 3 hours at 37°C.  






Analysis of PCR products
One μl of PCR product before and after restriction digestion was mixed with LIZ-500 size 
standard and formamide and run in two separate lanes on an AB 3100 genetic analyser set up 
for genotyping with 50 cm capillaries. Results were analysed using Genescan software version 
3.7 (Applied Biosystems, Carlsbad, CA, USA), and alleles were scored visually according to the 
following scheme: Uncut: S, 469 bp; L, 512 bp. Cut: Sg, 402 + 67 bp; Lg, 402 + 110 bp.
Instruments
Diagnosis. The Mini International Neuropsychiatric Interview (M.I.N.I.) was administered 
(Sheehan et al., 1997; Van Vliet et al., 2000) to assess psychiatric diagnoses.
Psychiatric symptoms and mood states. Three self-report questionnaires were used. 
Current symptoms of anxiety and depression were measured using the hospital anxiety and 
depression scale (HADS; Zigmond & Snaith, 1983; Spinhoven et al., 1997). The HADS is a 14-
item self-report scale which assesses past-week severity of anxiety and depressive symptoms. 
Positive and negative affect was assessed by means of the Positive and Negative Affectivity 
Scales (PANAS), a 20-item questionnaire (Watson et al., 1988). The state version (today) was 
used. The mood states Sadness, Annoyance, Tension and Anxiety were assessed using single-
item Mood States Scales (MSS) with scores ranging from 0 (not at all) to 10 (extremely).
Stress Induction 
The Trier Social Stress Test (TSST; Kirschbaum et al., 1993) is a combination of a public speaking 
task in front of an unresponsive audience and a mental arithmetic task at high speed and with 
public correction of every mistake. During an initial resting period of 50 minutes, baseline 
saliva cortisol samples were obtained at time points t15 and t50. Subsequently, participants 
were informed that they were about to give a speech in front of an audience consisting of 
three persons, and that they would also complete another task that this audience would 
announce to them (i.e. the mental arithmetic task). The TSST protocol further prescribes that 
participants were informed that their speech would be videotaped and evaluated by skilled 
psychologists with regard to content and performance. During the verbal instructions the 
experimenter briefly showed the room with the audience waiting for him/her. Subsequently, 
participants were placed in a quiet room and given six minutes to prepare themselves. They 
were instructed that it was not allowed to keep any notes during their speech. At the end 
of this anticipation period, another saliva sample was taken and the participant entered 
the room in order to deliver the speech and complete the arithmetic task. At the end of the 
arithmetic task, the experimenter entered the room and took another saliva sample in front 
of the audience. Subsequently, the participant was guided to a quiet room and was allowed 
to rest and read magazines for 45 minutes. Saliva samples were collected at six points in time 
(with t0 representing the time of arrival): rest 1 (t15), rest 2 (t50), after anticipation (t56), after 
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speech and arithmetic task (t65) and twice during the recovery period (t90 and t110). During 
saliva sampling participants rated their mood states on the MSS. 
Salivary cortisol assessment 
Salivary cortisol was assessed using Salicaps (IBL International, Germany). Saliva samples 
were stored at -20°C until assayed at the laboratory of biopsychology at the University 
of Dresden, Germany. Free cortisol concentrations in saliva were measured using a 
commercially available “Luminescence Immunoassay for the in-vitro-diagnostic quantitative 
determination of cortisol in human saliva and serum” (IBL, Hamburg, Germany). The intra 
and interassay coefficients of variance for cortisol was below 8%.  
Design and procedure
This study was a randomized double-blind placebo-controlled trial with stratification 
for genetic variation of the 5-HTTLPR genotype. Participants were randomly allocated 
to receive 7 capsules containing either TRP (total dose of 2.8 g/day) or placebo (cellulose 
microcrystalline) for a period of six days. The dosage and duration were based on previous 
studies that had shown social-behavioural effects of TRP administration (3 g/day) after a 
period of 15 days (Aan het Rot et al., 2006) and cognitive effects after a single dose of 0.8g 
TRP (Markus & Firk, 2009). The experimental procedure included two visits to the laboratory, 
pre- and post-TRP.
First visit to laboratory. 
Upon arrival at the laboratory, participants provided written informed consent for the study. 
Following the M.I.N.I. interview, participants performed experimental tasks and filled out 
questionnaires on a computer. At the end of the first visit, participants were provided with 42 
capsules that contained 400 mg tryptophan or placebo (PLC). Oral and written instructions 
were provided to the participants regarding the timing of administration of capsules and 
lifestyle restrictions during the next six days and on the day of the second lab visit. 
Tryptophan supplementation
Participants started to take the capsules the day after their first lab visit. They were instructed 
to take two capsules in the morning, two in the afternoon (before meals) and three in the 
evening (before 23.00h). Participants received a diary in which they were asked to write down 
the exact time of intake and number of capsules. Compliance was not measured through 
blood sample analyses, however participants were led to believe that compliance would be 
assessed at post-intervention through a saliva sample. 






Lifestyle instructions included: no smoking, no use of dietary supplements and vitamins and 
consumption of alcohol limited to 3 units/day. Participants were also instructed to refrain 
from alcohol and caffeine-containing consumptions and avoid high carbohydrate meals on 
the day of their second visit. Further instructions for the day of the second visit included: no 
eating and drinking one hour before arriving at the laboratory (except water), and no physical 
exercise at least two hours before arrival. Female participants were tested in the luteal phase 
of their menstrual cycle. All test sessions started in the afternoon between noon and 5pm. 
Second visit to laboratory
Upon arrival at the lab participants handed in their diary regarding the intake of capsules. In 
addition, they were asked to fill out a debriefing questionnaire regarding compliance to the 
instructions during the previous six days. They were also interviewed about their compliance 
to the instructions for the second lab visit. Next, participants were asked to perform a number 
of tests and to fill out questionnaires on a computer. Finally, participants performed the TSST. 





For the total sample of n = 581, genotype frequencies were as follows: SS, 16,9%;  SLg, 4,8%; 
LgLg, 0,7%; LaLg, 8,6%; SLa, 43%; LaLa, 26%.  Participants were divided on the basis of the 
triallelic classification (Lg alleles were collapsed with S variants into three genotype groups: 
S’/S’ (n = 130); L’/S’ (n = 300); L’/L’ (n = 151). Genotype frequencies were consistent with 
Hardy–Weinberg Equilibrium (χ2 (1) = 0.67; p = 0.41). We contacted 92 S’/S’ carriers and 92 
L’/L’ carriers by email. Sixty-four S’/S’ and 66 L’/L’ carriers expressed interest in the study. After 
screening for in- and exclusion criteria we included 26 S’/S’ and 22 L’/L’ participants. In each 
group, one participant dropped out before day 2. Analyses were conducted on 25 S’/S’ and 
21 L’/L’ carriers. 
 The first two participants (one S’/S’ and one L’/L’ carrier) received tryptophan single 
blind. Since the TSST panel was double-blind for these participants and no observer ratings 
were collected, we kept these participants in the analyses. The demographic details of both 
groups are shown in Table 1. Groups did not differ significantly on assessed demographic 
characteristics. One participant in the PLC group (S’/S’ carrier) had a current diagnosis of 
panic disorder, and one participant in the TRP group (S’/S’ carrier) had a specific phobia 
(needles). Both participants were not taking any medication.
Table 1. Demographic characteristics for both genotype groups.
 
T ble 1. 
Demographic characteristics for both genotype groups.  
 
     S’/S’  (S/S, S/Lg, Lg/Lg) L’/L’ (La/La) 
Female     11     11 
Male      14     10 
Age (M±SD)           20.4 ± 3.5             20.3 ± 2.5 
BMI (M±SD)           19.4 ± 3.0                          19.2 ± 1.7 
 
Note: Mean ± Standard Deviation.  Abbreviation: BMI, Body Mass Index.        
Note: Mean ± Standard Deviation. Abbreviation: BMI, Body Mass Index.
Compliance
According to self-report, approximately 98% of the capsules were taken according to 
instructions. The minimum percentage of capsules taken by a participant was 69%. Three 
participants had taken two capsules in the morning before the second lab visit. All these 
participants were retained. 






Effects of TRP on psychiatric symptoms  
In order to analyse the effects of intervention and genotype on psychiatric symptoms, separate 
RM-GLMs for each of the questionnaire scores (HADS Anxiety, HADS Depression, PANAS-S Pos 
and PANAS-S Neg) were conducted with Time as within subject factor, and Intervention (TRP 
vs. PLC) and Genotype (S’/S’ vs. L’/L’) as between subject factors. No significant effects were 
found for intervention or genotype (Table 2). 
Table 2. Symptom scores for each genotype and intervention group assessed pre- and post-intervention.
Table 2.  
 




Anxiety Depression Negative Affect Positive Affect 
S’/S’ TRP Pre 3.6 ± 2.0 1.9 ± 1.2 12.1 ± 4.3 30.1 ± 6.7 
 Post 3.8 ± 2.4 2.8 ± 2.8 13.3 ± 3.3 32.1 ± 5.2 
S’/S’ PLC Pre 4.8 ± 3.3 1.4 ± 1.6 12.8 ± 2.8 32.6 ± 4.0 
 Post 3.7 ± 3.7 1.3 ± 1.5 12.3 ± 2.3 34.6 ± 4.9 
L’/L’ TRP Pre 3.8 ± 2.4 1.4 ± 1.4 12.2 ± 2.7 30.3 ± 8.5 
 Post 4.2 ± 3.3 1.5 ± 1.4 11.9 ± 2.1 28.5 ± 8.9 
L’/L’ PLC Pre 3.9 ± 3.8 2.4 ± 2.6 13.1 ± 2.4 29. 5 ± 5.9 
 Post 3.7 ± 2.2 2.5 ± 2.3 15.4 ± 7.0 31.9 ± 8.2 
 
Note: Mean ± Standard Deviation. Abbreviations: TRP, tryptophan; PLC, placebo.  
 
Note: Mean ± Standard Deviation. Abbreviations: TRP, tryptophan; PLC, placebo.
Cortisol Response to TSST 
The cortisol data were not normally distributed. Log10-transformations were successful in 
normalizing the distributions. Analyses of transformed data are reported, but the figures 
represent untransformed data. RM-GLMs were conducted in the S’/S’ and L’/L’ groups 
separately on cortisol concentrations, with Time (the six cortisol measurements) as within 
subjects factor and Intervention (TRP vs. PLC) as a between subjects factor. Gender was 
included as covariate. Greenhouse-Geisser statistics are reported. In the S’/S’ group, the 
main effect of Time was significant (F(1.50, 33.07) = 6.72, p = 0.007, ηp²= 0.234) and the Time x 
Intervention interaction was borderline significant (F(1.50, 33.07) = 3.55, p =0.052, ηp²= 0.139). 
In the L’/L’ group, the main effect of Time was a trend (F(1.76, 31.70) = 3.09, p =0.065, ηp²= 
0.146) and the interaction was non-significant. Figure 1 displays the cortisol concentrations 
over time by intervention and genotype.
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Figure 1. Salivary cortisol (nmol/l) before, during and after exposure to social stress in S’/S’ group (Figure 1A) and 
in L’/L’ group (Figure 1B). 
To further probe the Time x Intervention interaction effect within the S’/S’ group, Independent-
samples t-tests were conducted, comparing cortisol concentrations at each time point 
between TRP- and placebo-treated individuals. Significant differences were observed at t65, 
t90 and t110. Within the S’/S’ group, the TRP-treated participants differed significantly from 






PLC-treated participants at t65 [t(19)=  -2.73, p= 0.012, d = 1.11]. Significant differences were 
also observed at t90 [t(23)=-2.27, p= 0.033, d=  0.92] and at t110   [t(23)=-2.29, p= 0.031 d=0.92]. 
Subjective mood response to TSST
A separate analysis was conducted for each scale of the MSS questionnaire. RM-GLMs with 
Time as within subjects factor, Intervention and Genotype as between subjects factors and 
Gender as covariate revealed a significant main effect of Time for the Tension scale (F(2.78, 
113.95) = 32.76, p < 0.01, ηp²= 0.444), Anxiety scale (F(1.77, 72.59) = 11.23, p < 0.01, ηp²= 
0.215) and Annoyance scale (F(2.37, 97.24) = 4.46, p = 0.01, ηp²= 0.098). Tension,  Anxiety and 
Annoyance scores varied between 0 and 5; after reaching a peak at t56 (after anticipation 
stress) and t65 (after speech and arithmetic task), the scores normalized to 0-1 at t90 and t110 
(rest) in all intervention and genotype groups. The ratings of sadness remained between 0 
and 1 at all time points (F(2.16, 88.72) = 0.41, p = 0.68, ηp²= 0.010) (Figure 2).
 




































Six days of TRP supplements attenuated the cortisol response to stress in S’/S’ carriers of the 
serotonin transporter gene. Following social stress, significantly lower cortisol concentrations 
were found in S’/S’ carriers treated with TRP than in S’/S’ carriers treated with placebo. TRP 
had no effect in L’/L’ carriers, whose cortisol curves were comparable to TRP-treated S’/S’ 
carriers. These effects of TRP on cortisol response to stress were observed in the absence of 
any effects on anxiety, depressive symptoms, or affect. Furthermore, neither genotype nor 
intervention had an effect on the subjective mood response to the TSST. 
 Previous studies have found differential HPA axis activity depending on 5-HTTLPR 
genotype (Gotlib et al., 2008; Alexander et al., 2009; Wüst et al., 2009; Way & Taylor, 2010, Mueller 
et al., 2010, Mueller et al., 2011), but the effects of TRP supplements on this association had 
not been investigated. Only one study has investigated the effects of TRP (single dose, 0.8g) 
in S’/S’ vs. L’/L’ individuals (Markus & Firk, 2009), and found no effect on the cortisol response 
to stress in either genotype group. Notably, in this prior study the stressor failed to produce 
a rise in cortisol. While the lack of a cortisol response to stress in control conditions negated 
the opportunity to observe a dampening of this effect, a small improvement of mood was 
noted after 0.8 g TRP in S’/S’ carriers but not in L’/L’ carriers.
In the present study, we found no effect of TRP on anxiety and depression symptoms or mood 
states during exposure to public speaking stress in either L’/L’ or S’/S’ carriers. While the 
present findings seem to conflict with those of Markus & Firk (2009), the latter utilized pooled 
mood states (pre- and post-intervention) and also employed a crossover design. This means 
that their participants were exposed to the same stressor twice. Anticipation stress may have 
been different during the second administration. Earlier studies, in which genotype had not 
been assessed, found only small and rather inconsistent effects of tryptophan loading on 
mood and stress response (Markus et al., 1998; Markus et al., 2000a; Markus et al., 2000b; 
Merens et al., 2005; Markus, 2007; Nesic & Duka, 2008; Firk & Markus, 2009; Markus et al., 
2010).  In contrast to the aforementioned studies, we pre-selected our participants based on 
genotype, used a longer intervention period of six days, and carefully selected participants to 
eliminate potential confounders as much as possible (e.g. use of contraceptives; smoking).
 Although the complex relationship between HPA axis reactivity and 5-HTTLPR 
genotype remains to be further elucidated, several studies have indicated that neurobiological 
responses to negative or threatening stimuli are mediated by 5-HTTLPR genotype. Healthy S 
carriers had greater amygdala reactivity to negative facial expressions (e.g., fearful and angry) 
than L/L carriers in a face matching task (Hariri et al., 2002; Hariri et al., 2005). If 5-HTTLPR 
affects amygdala response to negative environmental stimuli in general, this may in turn 
also mediate HPA axis reactivity (Way and Taylor, 2009).  At the molecular level the serotonin 
transporter promoter polymorphism alters SLC6A4 transcription efficiency and the level of 






serotonin transporter function (Lesch et al., 1996; Greenberg et al., 1999). It remains unclear 
exactly how the 5-HTT polymorphism alters neurochemical processes between the pre- and 
post- synaptic cells. 5-HTTLPR genotype-related alterations found so far include: differential 
levels of extracellular 5-HT concentrations, difference in 5-HT clearance, changes in tissue 
5-HT concentrations, and 5-HT synthesis and turnover in the brain (as reviewed by Murphy & 
Lesch, 2008). Since the short variant is associated with reduced uptake or clearance of 5-HT 
as compared with the long variant, it is also associated with higher concentrations of 5-HT in 
the synaptic cleft. Consequently, presynaptic 5HT1A autoreceptors may be overstimulated 
in S carriers by the increased 5-HT concentrations. The negative feedback mechanism of 
these autoreceptors causes a decrease in 5-HT synthesis in the presynaptic cell, reducing the 
amount of 5-HT in the synapse (Hoyer et al., 1994). Subchronic administration of TRP might 
compensate this process and result in an attenuated cortisol response to social stress.
In summary, the 5-HTT polymorphism changes the dynamic between post- and pre- synaptic 
cell and this may also influence peripheral adrenomedullary and hypothalamo-pituitary 
responses (Murphy & Lesch 2008). As the precise neurochemical differences between S’ and 
L’ carriers remain unclear, the underlying mechanisms of our findings remain speculative. 
 
Limitations and future directions
Limitations of our study include the relatively small sample size and the fact that we checked 
compliance only by self-report and not by measuring TRP concentrations in plasma before 
and after intervention. Self-reported compliance was excellent. To optimize compliance, 
participants kept a diary of the exact time of intake of capsules and had been led to believe 
that compliance would be checked through a saliva sample.
 TRP supplementation of six days (2.8 g/day) may be used in further studies as 
an experimental intervention to increase TRP levels in 5-HT vulnerable populations (i.e. 
serotonergic genotypes associated with stress vulnerability). In this study we have shown 
that a group with a specific genotype seems to benefit more from TRP supplements, as TRP 
attenuated the cortisol response to stress. Future studies may investigate whether the same 
effects can also be reached with lower dosages of TRP supplementation. Another essential 
question that needs to be answered is the maximum duration of the intervention. The daily 
requirement of tryptophan for humans is between 3 and 5 mg/kg per day (World Health 
Organization, 2002). We administered 2800 mg/day, which is almost ten times this daily 
requirement. Although high tryptophan intake has no serious adverse effects in animals 
and humans (Garlick, 2004), the mechanism and safety of long-term and high-dose TRP 
supplementation needs further investigation (Le Floc’h et al., 2010). For instance, cognitive 
dysfunctions have been observed after intravenous TRP infusion in healthy first-degree 
relatives of patients with bipolar disorder (Sobczak et al., 2003). In ‘quarrelsome’ individuals, 
however, a high dose of tryptophan (3 g/d) for 15 days decreased quarrelsome behaviours 
and increased agreeableness (Aan het Rot et al., 2006).  Future studies may further investigate 
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how the effects of TRP supplements on the cognitive, physiological and behavioural levels 
depend on serotonergic genotypes. Research on TRP supplementation in individuals 
with serotonergic genotypes conferring vulnerability to stress might give new insights in 
personalized treatment of mood disorders. 
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The Effect of 5-HTTLPR Genotype and 
Tryptophan Supplementation on the Response 
to Unfairness in Healthy Volunteers





Experimental manipulation of the availability of serotonin (5-HT) has been shown to 
increase or decrease the rejection rates of unfair offers in the Ultimatum Game (UG). The 
effect of 5-HT manipulations on UG performance may also be moderated by genotypic 
variation, in particular the 5HT-transporter-linked polymorphic region (5-HTTLPR). The aim 
of the present study was to investigate the effect of 5-HTTLPR genotype, tryptophan (TRP) 
supplementation and their interaction on performance on the UG in healthy individuals. 
The UG was completed by 26 S’/S’ and 21 L’/L’ carriers of the 5-HTTLPR, before 
and after a 6-day intervention of TRP (2.8 g/day) or placebo. We also measured 
impulsivity with a response inhibition (Go-Stop) task and with a questionnaire. 
5-HTTLPR genotype did not affect the rejection rate to unfair offers. TRP supplementation 
also had no effect, but there was a non-significant tendency in the opposite direction as 
expected: the TRP-group had higher rejection rates of very unfair offers than the placebo 
group. Neither genotype nor intervention had an effect on impulsivity. A limitation of this 
study is that no blood samples were taken. The lack of effects cannot be explained by low 
statistical power and/or weakness of the intervention since the effect went in the opposite 
direction as expected. Our findings are not consistent with earlier studies with other 5-HT 
manipulations.







Serotonin (5-HT) is involved in the modulation of many aspects of social cognition and 
behaviour. Genotypic variation, in particular regarding the serotonin transporter gene 
(SLC6A4) affects social cognition (Canli & Lesch, 2007), as well as 5-HT manipulations. For 
instance, experimental depletion of tryptophan (TRP), a precursor of 5-HT, leads to reduced 
cooperative behaviour in a Prisoners Dilemma paradigm (Wood et al., 2006). TRP depleted 
healthy volunteers judged couples as less intimate and less romantic (Bilderbeck et al., 2011). 
TRP depletion also increased reaction times for happy but not sad faces in an affective go/no 
go task (Murphy et al., 2002) and increased rapid- response impulsivity in healthy volunteers 
(Walderhaug et al., 2002). Serotonin also plays a role in the processing of facial expressions 
and social interactions. For example, acute tryptophan depletion (ATD) decreased the 
recognition of fearful facial expressions in healthy females (Harmer et al., 2003) and TRP 
supplementation for 15 days decreased quarrelsomeness in quarrelsome men and women 
and altered the perception of others in the quarrelsome males (Aan het Rot et al., 2006). 
These studies show that lowering serotonin availability is associated with disruptive social 
behaviour, whereas increasing serotonin availability is associated with pro-social perception 
and behaviour.
 Serotonergic manipulations also affect performance in the Ultimatum Game (UG) 
(Crockett et al., 2008; Crockett et al., 2010). In the UG, the participant (responder) is exposed 
to offers to split a sum of money from other individuals. The responder can either accept 
the offer (in which the money is divided accordingly) or reject the offer (in which case both 
players receive nothing). Rationally, the responder should accept every offer regardless of its 
fairness to earn the most. However, very unfair offers (20% of the total) have a 50% chance of 
being rejected (Güth, Schmittberger & Schwartze 1982; Bolton & Zwick, 1995), which indicates 
that emotion plays an important role in making those decisions. Acute tryptophan depletion 
was associated with a higher rejection rate (approximately 81%) of very unfair offers (18-22% 
of the stake) than PLC (appr. 65%) in healthy individuals (Crockett et al., 2008). This effect 
was independent of the size of the offer and ATD had no effect on self-reported mood or 
on response inhibition. Conversely, a single dose of a selective serotonin reuptake inhibitor 
(SSRI), citolapram (30 mg) was associated with a lower rejection rate (appr. 34%) of unfair 
offers than PLC (appr. 48%) and atomoxetine (60 mg) a selective selective nor epinephrine 
reuptake inhibitor (NRI), (appr. 50%) in 30 healthy participants (Crockett et al., 2010). This 
time the effect was restricted to moderately unfair offers (27-33% of the stake). Citalopram did 
not alter self-reported mood. In another study, healthy students who rejected an unfair offer 
had lower platelet serotonin content than participants who accepted the offer (Emanuele 
et al., 2008). Finally, a PET study in 20 healthy males showed that individuals with low levels 
of 5-HT transporter binding in the dorsal raphe nucleus were more likely to reject unfair 
offers (Takahashi et al., 2012).  In summary, UG behaviour seems to be under serotonergic 
influence and the effects are consistent across studies. The direction of the effect on the UG 
CHAPTER 5
96
is consistent with the direction of the 5-HT manipulation (Crocket et al., 2008; Crocket et al., 
2010). 
 Although 5-HTTLPR genotype is linked to social cognition (Canli & Lesch, 2007; 
Antypa et al., 2011), no studies have been conducted in order to investigate whether 
5-HTTLPR moderates the effect of 5-HT manipulations on UG performance. In the present 
study we investigated whether performance on the UG is affected by 5-HTTLPR genotype and 
by an increase of 5-HT availability through tryptophan (TRP) supplementation. Specifically, 
short and long allele carriers of the 5-HTTLPR completed the UG prior to and after a 6-day 
intervention of TRP (2.8 g/day) or placebo. In a previous report on this study, we have shown 
that TRP normalized the cortisol response to social stress in S’/S’ carriers only (Cerit et al., 
2013). Based on the less efficient serotonin neurotransmission in S’/S’ carriers, the regulation 
of the reaction to unfairness was expected to be diminished in this group. We hypothesized 
that we would find higher rejection rates in S’/S’ carriers than in L’/L’ carriers and that this 
difference would be reduced after 6-day TRP supplementation. Response inhibition (Go-Stop 
task) and self-reported impulsivity (BIS-II) were measured as secondary outcomes. Based on 
Crockett et al. (2008) we expected a selective effect on the ultimatum game. 






Methods and Materials 
Participant pool 
The participants of this study are the same as reported in Cerit et al. (2013). Participants 
were selected from a pool of 581 genotyped individuals who were non-smokers and whose 
grandparents were all West-European. The age range was 18 to 35 years and Body Mass Index 
was between 19 and 29 kg/m². Exclusion criteria were a current diagnosis of depression 
or post-traumatic stress disorder, a lifetime history of psychosis, and use of medication, 
including oral contraceptives. Genotype frequencies were as follows: SS, 16,9%;  SLg, 4,8%; 
LgLg, 0,7%; LaLg, 8,6%; SLa, 43%; LaLa, 26%.  Participants were divided on the basis of the 
triallelic classification (Lg alleles were collapsed with S variants into three genotype groups: 
S’/S’ (n = 130); L’/S’ (n = 300); L’/L’ (n = 151). Genotype frequencies were consistent with 
Hardy–Weinberg Equilibrium (χ2 (1) = 0.67, p = 0.41).
 We invited only participants with two low-expressing alleles (S’/S’:  S/S, S/Lg and 
Lg/Lg variants) or two high-expressing alleles (L’/L’:  La/La). Written informed consent was 
obtained before data collection. The research was approved by the Medical Ethics Committee 
of Leiden University Medical Centre in The Netherlands. Participants received € 40 upon 
completing the study.
Genetic Assessment
DNA was obtained using the Oragene Self-Collection Kit – DISC format (DNA Genotek Inc, 
Ottawa, ON, Canada); 200 µl of saliva was collected in lysis buffer (100 mM NaCl, 10 mM EDTA, 
10 mM Tris pH 8, 0.1 mg/ml proteinase K and 0.5% w/v SDS) until further processing. Genomic 
DNA was isolated from the samples using the Chemagic buccal swab kit on a Chemagen 
Module I workstation (Chemagen Biopolymer-Technologie AG, Baesweiler, Germany). DNA 
concentrations were quantified by OD260 measurement and by agarose gel electrophoresis. 
The average yield was approximately 4 µg of genomic DNA per sample.
Polymerase chain reaction amplification 
The region of interest from the 5-HTT gene was amplified by triplex PCR using the following 
primers: a FAM-labeled primer HTTLPR-FWFAM 5’-TCCTCCGCTTTGGCGCCTCTTCC-3’, and 
a reverse primer HTTLPR-RV 5’-TGGGGGTTGCAGGGGAGATCCTG-3’. Typical PCR reactions 
contained between 10 and 100 ng genomic DNA template, 10 pmol of forward and 
reverse primer. PCR was carried out in the presence of 5% DMSO with 0.5U of BioThermAB 
polymerase (GeneCraft, Munster, Germany) in a total volume of 30 ml using the following 
cycling conditions: initial denaturation step of 5 min at 95°C, followed by 40 cycles of 30 sec 
96°C, 30 sec 61°C, 60 sec 72°C and a final extension step of 10 min 72°C. After PCR 5 µl of the 
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sample was subjected to restriction digestion with the enzyme HpaII in a total volume of 20 
µl. Restriction enzyme mix was incubated with DNA for 3 hours at 37°C.  
Analysis of PCR products
One μL of PCR product before and after restriction digestion was mixed with LIZ-500 size 
standard and formamide and run in two separate lanes on an AB 3100 genetic analyser set up 
for genotyping with 50 cm capillaries. Results were analysed using Genescan software version 
3.7 (Applied Biosystems, Carlsbad, CA, USA), and alleles were scored visually according to the 
following scheme: Uncut: S, 469 bp; L, 512 bp. Cut: Sg, 402 + 67 bp; Lg, 402 + 110 bp.
Instruments
Diagnosis. The Mini International Neuropsychiatric Interview (M.I.N.I.) was administered 
(Sheehan et al., 1997; Van Vliet et al., 2000) to assess psychiatric diagnoses.
Ultimatum Game. The ultimatum game consists of three different conditions in which 
participants are exposed to fair (45% of stake), unfair (32% of stake) and most (i.e. very) 
unfair (21% of stake) offers from a “proposer”, who had split a sum of money given by the 
experimenter. If the participant accepts the offer, both the proposer and participant will 
receive the money as promised in the offer. In case of a rejection by the participant neither 
one will receive money. An example of a highly unfair offer could be € 2 for the participant and 
€ 8 for the proposer. Obviously, the most beneficial strategy economically for the participant 
is to accept each offer regardless of its fairness level. Next to social reward (fairness), monetary 
reward (offer size) was also manipulated as described in Crockett et al. (2008). The value of 
the stake was either low (between 1 and 7 euro) or high (between 8 and 33 euro). 
 After 10 practice trials, participants were asked to respond to 48 offers (16 per 
fairness level). With each offer a photograph of a new proposer, the amount of the stake, and 
the amount of the offer was shown. The 48 photographs were counterbalanced for gender 
(24 male and 24 female proposers). All 48 offers were presented in a random order at both 
sessions. The participants were told that they would receive a percentage of the total amount 
that they had gained after having completed both sessions. In reality, there were no actual 
proposers and all participants received the same propositions. To increase credibility, the 
participants were first asked to split 24 sums of money (on paper) and had their photograph 
taken to be used in future experiments. 
Impulsivity. Self-reported impulsivity was assessed with the 30-item Barratt Impulsiveness 
Scale (BIS-II, state version; Patton et al., 1995). The Go-Stop test is a stop-signal task and 






measures response inhibition aspects of impulsivity (Dougherty 2005; Dougherty et al., 
2010). In this task a series of 5-digit numbers are displayed for 500 msec with a 1,500 msec 
inter-stimulus interval. The 5-digit numbers appear in series, and some of these numbers 
are identical to the immediately preceding 5-digit number. Participants are instructed to 
respond to these matching numbers (Go Signal). Some of these matching numbers are first 
presented in black and then suddenly turn red. This is a Stop Signal cue, and the participants 
are instructed to withhold responding to any matching numbers that turn red. The timing 
of these stop signals varied across the testing session (e.g. 50, 150, 250 and 350 msec). The 
two dependent measures of interest were: 1) correct responses and 2) response inhibition 
failures. The primary dependent measure is the Go-Stop Ratio, which is the ratio of these 
two measures. The Go-Stop Ratio has been validated as a measure of the ability to inhibit an 
already initiated response, and data from the 150 msec stop delay typically provides the best 
group discrimination (Dougherty et al., 2010).
Design and procedure
This study was a randomized double-blind placebo-controlled experimental study with 
stratification for genetic variation of the 5-HTTLPR genotype. Participants were randomly 
allocated to receive 7 capsules containing either 400 mg TRP (total dose of 2.8 g/day) or 
placebo (cellulose microcrystalline) for a period of six days. The dosage and duration were 
based on previous studies that had shown social-behavioural effects of TRP administration 
(3 g/day) after a period of 15 days (Aan het Rot et al., 2006) and cognitive effects after a single 
dose of 0.8g TRP (Markus & Firk, 2009). The experimental procedure included two visits to the 
laboratory on the days before and after the intervention (Day 0 and 7).
First visit to laboratory (Day 0)
Upon arrival at the laboratory, participants provided written informed consent. Following 
the M.I.N.I. interview, participants filled out the BIS-II, and completed the ultimatum game 
and Go-Stop test, respectively (as part of a larger test battery). At the end of the first visit, 
participants were provided with 42 capsules that contained 400 mg tryptophan or placebo 
(PLC). Oral and written instructions were provided to the participants regarding the timing of 
administration of capsules and lifestyle restrictions during the next six days and on the day 
of the second lab visit. 
Tryptophan supplementation
Participants started to take the capsules the day after their first lab visit. They were instructed 
to take two capsules in the morning, two in the afternoon (before meals) and three in the 
evening (before 23.00h). Participants received a diary in which they were asked to write down 
the exact time of intake and number of capsules. Compliance was not measured through 
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blood sample analyses, however, participants were led to believe that compliance would 
be assessed at post-intervention through a saliva sample. Lifestyle instructions included: no 
smoking, no use of dietary supplements and vitamins and consumption of alcohol limited 
to three units/day. Participants were also instructed to refrain from alcohol and caffeine-
containing consumptions and avoid high carbohydrate meals on the day of their second 
visit. Further instructions for the day of the second visit included: no eating and drinking one 
hour before arriving at the laboratory (except water), and no physical exercise at least two 
hours before arrival. Female participants were tested in the luteal phase of their menstrual 
cycle. All test sessions started in the afternoon between noon and 5pm. 
Second visit to laboratory (Day 7)
Upon arrival at the lab, participants handed in their diary regarding the intake of capsules. In 
addition, they were asked to fill out a debriefing questionnaire regarding compliance to the 
instructions during the previous six days. They were also interviewed about their compliance 
to the instructions for the second lab visit. Next, participants were asked to complete the BIS-
II questionnaire, the Ultimatum Game and Go-Stop test in fixed order. 








We contacted 92 S’/S’ carriers and 92 L’/L’ carriers from our participant pool (N=581) by email. 
Sixty-four S’/S’ and 66 L’/L’ carriers expressed interest in the study. After screening for in- and 
exclusion criteria we included 26 S’/S’ and 22 L’/L’ participants. In L/’L group, one participant 
dropped out before the second visit to laboratory. Analyses were conducted on 26 S’/S’ and 
21 L’/L’ carriers. 
The first two participants (one S’/S’ and one L’/L’ carrier) who received tryptophan single 
blind were kept in the analysis. The demographic details of both groups are shown in Table 
1. Groups did not differ significantly on demographic characteristics. One participant in the 
PLC group (S’/S’ carrier) had a current diagnosis of panic disorder, and one participant in 
the TRP group (S’/S’ carrier) had a specific phobia (for needles). Both participants were not 
taking any medication.








Demographic Characteristics of the Tri-Allelic S’/S’ and L’/L’ 5-HTTLPR Genotype 
groups 
   S’/S’ (N = 26)  L’/L’ (N = 21)  
 
Age (M±SD)  20.4 ± 3.4  20.3 ± 2.5 
Females/males 12/14   11/10 
 




*Note: S’/S’ includes: S/S, S/Lg, Lg/Lg and L’/L’ includes:  La/La; M, Mean; SD, Standard Deviation.
Compliance
According to self-report, approximately 98% of the capsules were taken according to 
instructions. The minimum percentage of capsules taken by a participant was 69%. Three 
participants had taken two capsules in the morning of the second lab visit. All these 
participants were retained. 
 
Ultimatum Game
Genotype Effect on ultimatum game on Day 0. A Repeated Measures ANOVA (RM-ANOVA) with 
Offer size (low and high) and Fairness level (fair, unfair and most unfair) as within subjects 
factors and Genotype (S’/S’ and L’/L’) as between subjects factor on the rejection rates on 
Day 0 (pre-intervention) was conducted. This analysis revealed the expected main effects 
of Offer size (F (1.00, 45.00) = 5.66, p = 0.022, ηp²= 0.112) and Fairness level (F (1.66, 74.60) = 
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100.49, p < 0.001, ηp²= 0.691). The interaction of Offer size and Fairness was also significant 
(F (1.833, 82.49) =, p = 0.039, ηp²= 0.072). No main or interaction effects involving genotype 
were found. 
Genotype and intervention effects on ultimatum game on Day 0 and 7. A 2x2x3 RM-ANOVA 
with Time (pre/post intervention), Offer size and Fairness level as within subjects factors 
and Genotype and Intervention (TRP/PLC) as between subjects factors again revealed the 
expected main effects of Offer size and Fairness level (F (1.54, 66.26) = 112.44, p < 0.001, 
ηp²= 0.723), but no main effects of Genotype, Time or Intervention. However, three-way 
interactions among Time x Offer size x Genotype (F (1.00, 43.00) = 6.22, p = 0.017, ηp²= 0.126) 
and Time x Offer Size x Intervention (F (1.00, 43.00) = 8.12, p = 0.007, ηp²= 0.159) were found. 
Separate RM-ANOVAs with Time as within subject factor and Intervention as between subject 
factor were conducted on the rejection rates of high unfair, high most unfair, low unfair and 
low most unfair offers. None of these analyses revealed a main effect of time or intervention. 
However, in the analysis of the High Most Unfair offers, a significant Time x Intervention was 
found (F (1.00, 45.00) = 4.249, p = 0.045, ηp²= 0.086) (Figure 1). The interaction was borderline 
significant (p = 0.057) when genotype was included as a between subjects factor. We 
conducted post-hoc Independent-Sample T-Test on day 7, and Paired-Sample T-Tests within 
the TRP and PLC groups separately. None of these analyses revealed a significant difference 
(all p-values around 0.15). 




































Rejection rates of “Most Unfair” offers with High offer sizes pre- and post-intervention 
 
(TRP; Tryptophan, PLC; Placebo) 
Note: Rejection rates of “most unfair offers” with high offer sizes pre and post intervention (TRP; Tryptophan, 
PLC; Placebo). Error bars represent Standard Error (SE)







Genotype Effect on impulsivity on Day 0. In order to assess effects of 5-HTTLPR genotype on 
impulsivity a RM-ANOVA with the Attentional, Motor and Non-planning scales of the BIS-II 
measured at Day 0 (pre-intervention), as within subjects factors and Genotype (S’/S’ and L’/L’) 
as between subjects factor on the scores of the three scales revealed a main effect of scale 
(F (1.96, 88.09) = 144.54, p < 0.001, ηp²= 0.763). Impulsivity did not interact with Genotype (F 
(1.96, 88.09) = 0.445, p = 0.638, ηp²= 0.010). 
Genotype or intervention effects on impulsivity on Day 0 and 7. Effect of 5-HTTLPR genotype 
and intervention were assessed by conducting a RM-ANOVA with Time (pre/post intervention), 
and the three BIS-II scales as within subjects factors. Genotype and Intervention (TRP/PLC) 
were between subjects factors. No main effect of Time (F (1.00, 43.00) = 0.166, p = 0.686, ηp²= 
0.004) was found. A main effect of Impulsivity (F (1.98, 84.92) = 183.34, p < 0.001, ηp²= 0.810) 
and Time x Impulsivity was found (F (1.68, 72.17) = 4.829, p = 0.015, ηp²= 0.101).
Time x Impulsivity x Genotype was not significant (F (1.68, 72.17) = 2.483, p = 0.100, ηp²= 
0.055). Time x Impulsivity x Intervention was also not found (F (1.68, 72.17) = 1.688, p = 0.196, 
ηp²= 0.038). The scores on Attentional, Motor and Non-planning scales of the BIS-II are shown 
in Table 2. 
Go-Stop Task
Genotype Effect on Response Inhibition on Day 0. RM‐ANOVA with two impulsivity outcomes 
of the Go-Stop paradigm (Response Inhibition Failure and Correct Detections) as within 
subjects factors and Genotype (S’/S’ and L’/L’) as between subject factor on Day 0 (pre-
intervention), revealed a main effect of impulsivity outcome (F (1.00, 43.00) = 1200.20, p < 
0.001, ηp²= 0.96) interaction, but no effect of Genotype on the two impulsivity outcomes were 
found. 
A separate One-Way ANOVA was conducted for the Go-Stop Ratio outcome with Go-Stop 
Ratio on Day 0 as dependent variable and Genotype as factor. The genotype groups did not 
differ on the Go-Stop Ratio outcome (F (1, 45) = 1.415, p = 0.241).  
Genotype and intervention effects on Response Inhibition on Day 0 and 7. RM‐ANOVA with 
Time (pre/post intervention), and the two impulsivity outcomes of the Go-Stop paradigm 
(Response Inhibition Failure and Correct Detections) as within subjects factors, and Genotype 
and Intervention (TRP/PLC) as between subjects factors revealed a significant main effect 
of Impulsivity outcome, but no main effect on Time (F (1.00, 43.00) = 0.037, p = 0.848, ηp²= 
0.001). No effect of genotype or Intervention on impulsivity outcomes on Day 0 and Day 7 
were found (Table 3). 
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A separate RM-ANOVA with Time (pre/post intervention), and the Go-Stop Ratio outcome 
as within subjects factors, and Genotype and Intervention (TRP/PLC) as between subjects 
factors revealed a main effect of Time (F (1.00, 43.00) = 11.89, p = 0.001, ηp²= 0.217), but no 
interaction effects. 
Table 2. Self- reported Impulsivity. BIS-II scores on the 2cnd order factors Attentional, Motor and Non-Planning 








Self- rep rted Impulsivity. BIS-II scores on the 2cnd order factors Attentional, Motor 
and Non-Planning with Intervention (TRP and PLC) and Genotype (S’/S’ and L’/L)*, 
(Mean ± SD) 
                 Pre (M ± SD)   Post (M ± SD) 
Attentional TRP S’/S’  16.3 ± 2.4   15.9 ± 2.6 
   L’/L’  14.4 ± 2.5   14.6 ± 2.6  
  PLC S’/S’  15.3 ± 4.0   13.9 ± 3.5  
   L’/L’  15.1 ± 3.9   14.7 ± 3.2  
Motor  TRP S’/S’   22.1 ± 3.8   23.1 ± 3.3 
   L’/L’  20.8 ± 2.4   21.1 ± 2.3 
  PLC S’/S’  20.0 ± 2.6   21.5 ± 3.4 
   L’/L’  21.0 ± 3.7   21.5 ± 4.1  
Non-planning TRP S’/S’  27.0 ± 3.9   25.3 ± 3.6 
   L’/L’  26.2 ± 3.3   25.6 ± 3.4 
  PLC S’/S’  25.0 ± 3.4   24.2 ± 3.7 
   L’/L’  23.3 ± 4.0   23.9 ± 4.7  
(M, Mean; SD, Standard Deviation; TRP, Tryptophan; PLC, Placebo)  
*Note: S’/S’ includes: S/S, S/Lg, Lg/Lg and L’/L’ includes:  La/La 
 
, ean; SD, Standard Deviation; TRP, Tryptophan; PLC, Placebo) 
*Note: S’/S’ includes: S/S, S/Lg, Lg/Lg and L’/L’ includes:  La/La















Go-Stop Impulsivity Measures at 150 ms, (Mean ± SD) 
        Pre (M ± SD)   Post (M ± SD) 
TRP    
Correct detections     67.28 (12.03)  63.36 (23.01)    
Response Inhibition Failure    0.37 (0.20)  0.33 (0.20)          
Go-Stop Ratio     0.48 (0.25)  0.36 (0.21) 
PLC 
Correct detections     63.18 (13.62)         65.91 (14.51) 
Response Inhibition Failure     0.42 (0.20)    0.36 (0.23) 







Genotypic variation of the 5-HTTLPR did not influence the response of healthy participants 
to unfair offers. Six days of tryptophan supplementation seemed to influence response to 
very unfair offers, however, this effect did not reach statistical significance. We also found no 
effects of genotype, intervention or their interactions on impulsivity as measured by the Go-
Stop Task or by self-report.
 Our findings are not consistent with other studies in which the ultimatum game 
was performed by healthy participants following a serotonergic manipulation. A single dose 
of citalopram reduced the rejection rate of unfair offers compared to placebo condition in 
healthy volunteers (Crockett et al., 2010), whereas tryptophan depletion had an opposite 
effect (Crocket et al., 2008). In another study, low platelet serotonin was found to be associated 
with heightened rejection of unfair offers (Emanuele et al., 2008). Our non-significant findings 
were in the opposite direction as these three studies, which suggest that our findings were 
not due to low statistical power. Insufficient strength of our intervention is also unlikely, since 
we did observe an attenuated cortisol response to social stress in S’/S’ carriers, as reported 
previously (Cerit et al., 2013).  
 It is conceivable that the ultimatum game may be less sensitive when administered 
more than once. This cannot explain the lack of effect of genotypic variation, but might 
explain the findings regarding tryptophan supplements. Participants may have applied 
different strategies during the two experimental sessions. However, others (e.g., Crockett et 
al., 2008) have also administered the UG more than once.
 Our participants did not take TRP on the day of testing. Therefore, one might argue 
that the opposite trend in our findings is due to the acute withdrawal of tryptophan that 
caused a relative depletion. Since we did not take blood samples, we cannot be sure about 
the tryptophan concentrations at the time of testing. This relative depletion hypothesis 
seems quite unlikely, considering that we found a reduced cortisol response to social stress 
in the same participants, which is theoretically consistent with supplementation (Cerit et al., 
2013). 
 We have no information on the diet of the participants during the 6-day lasting 
TRP intervention, neither do we have information on the type of meal that participants 
have consumed on day 7. We did not take blood samples to measure peripheral parameters 
(e.g. TRP/LNAA ratios) which could provide us with 1) an indication of a possible interaction 
of nutrients with the intervention during the study and/or 2) an indication of the effect of 
the intervention on central serotonin levels. However, the aim of the current study was not 
to measure the acute effect of TRP loading on central serotonin levels and its consequent 
effect on behaviour. The perspective of the current study is rather based on the idea that 
increasing serotonin availability leads to a shift from negative towards positive  information 






processing (Harmer et al., 2009) and alters social behaviour and perception of others in a 
positive manner (Aan het Rot et al., 2006). 
 The effects of 5-HT manipulations on UG behaviour may be mediated by more 
complex underlying processes than we had presumed. For example, the personality 
trait “agreeableness” was found to be a mediating factor between 5-HTT binding and UG 
behaviour in healthy men: higher scores on “straightforwardness” and “trust” (two subscales 
of “agreeableness”) were correlated with lower 5-HTT binding and higher rejection rates of 
unfair offers (Takahashi et al., 2012). Further studies are required to unravel the underlying 
processes between 5-HT neurotransmission and behavioural responses to unfairness. 
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Aim of the dissertation
The aim of this dissertation was to investigate the antidepressant properties of two 
compounds: a novel compound, ARA290, and a well-known compound, L-tryptophan.
ARA290 is a relatively new compound and studies on its effects on cognition and behaviour in 
healthy individuals are sparse. We used a neuropsychological model of drug action (Harmer 
et al., 2009) to test its possible antidepressant effects  in healthy volunteers. As summarized in 
the introduction, this model has been validated with registered antidepressants and is based 
on the finding that single dose or short term (1 week) administration of antidepressants 
in healthy volunteers results in a shift towards a more  positive bias in various domains 
of emotional information processing such as attention, memory and recognition of facial 
expressions (Harmer et al., 2011).  This early shift in emotional information processing may 
also be reflected in physiological (startle response) and neural changes (BOLD response) in 
healthy volunteers (Harmer et al., 2011).  In sum, the validated neuropsychological model of 
drug action includes behavioural, psychological and  neural measures that can be applied 
in order to detect early antidepressant-like effects of new compounds in healthy volunteers. 
It is suggested that this model provides an early indication of how promising/efficient a new 
compound may eventually be in clinical populations (Harmer et al., 2009; Harmer et al., 
2011). In addition to the primary outcomes of the neuropsychological model of drug action, 
which tap into emotional information processing, we also included resting-state fMRI as a 
measure in order to investigate the effects of ARA290 on resting-state connectivity. 
Next to a new compound ARA290, we also investigated the antidepressant properties 
of a better-known compound, L-tryptophan which has been investigated as an add-on 
compound to conventional antidepressants (Coppen et al., 1963; 1972). Since the effect 
of tryptophan manipulations on social-emotional information processing in healthy 
populations is relatively well known (Moskowitz et al., 2001; Aan het Rot et al., 2006; 2010), we 
aimed to further investigate the antidepressant effects of L-tryptophan by testing its effects 
in a healthy population possessing a genetic marker (serotonin transporter polymorphism) 
that is linked to depression vulnerability.
In order to assess the potential therapeutic effects of L-tryptophan, a selection of measures 
were applied. These measures include comparable behavioural and physiological 
vulnerability markers as those included in the neuropsychological model of drug action. The 
selection was based on recent studies on the effects of serotonin manipulations on cognition. 
Specifically, social-emotional decision making (behavioural) and stress or HPA-axis reactivity 
(physiological) were investigated. 
The assessment of neuropsychological effects of interventions in healthy individuals has the 







their cognitive performances are not ‘contaminated’ by earlier pharmacological treatment. 
The idea is that vulnerability markers of depression are also present to varying degrees in 
healthy individuals who do not have a history of depression.  The neuropsychological effects 
of ARA290 and tryptophan in healthy individuals were assessed by comparing placebo and 
intervention groups who had not had earlier treatment. 
1a. Does ARA290, a novel pharmacological compound, have antidepressant effects? 
Although a single dose of ARA290 (i.v. 2 mg) in healthy individuals did show an effect on some 
measures of the neuropsychological model of drug action, the effects were  small and not 
all of these were in the expected direction of an antidepressant effect. Specifically, ARA290- 
treated individuals had smaller neural responses to happy faces in the fusiform gyrus, but no 
neural differences during the memory task. Furthermore, ARA-290 was not associated with 
changes in the functional connectivity of the brain. At the behavioural level, ARA290 had no 
effect on the recognition of emotions in facial expressions. ARA290 did have an effect on the 
categorization of self-referential words as ARA290 was associated with faster categorization 
of positive vs negative words, but not with a better memory for positive words. Furthermore, 
ARA290 was associated with a higher positive attentional bias score than placebo. No effects 
of ARA290 were observed on measures of mood and psychiatric symptoms. Taken together, 
these findings suggest that a single administration of ARA290 elicited the expected shift 
from positive to a negative bias on two measures of the emotional test battery. These were 
not the primary outcome measures, however – these outcome measures are a part of the 
emotional test battery and are based on previous effects of registered antidepressants or 
EPO. Furthermore, since we had no baseline assessments, it cannot be excluded that the 
effects represent pre-existing group differences. 
1b. Effects of ARA290 - Limitations
Developed as an analogue of EPO, ARA290 is a peptide consisting of 11-amino acids which 
acts on the Innate Repair Receptor (IRR). The IRR consist of a β-common receptor (βCR) 
subunit (CD131) coupled to an  EPO receptor (EPOR) and its activation initiates signalling 
pathways that mediate tissue protection, without initiating hematopoietic effects (Review, 
Brines and Cerami, 2012). Considering a) the tissue protective and anti-inflammatory role 
of ARA290 in animals and humans (Pulman et al., 2013; Dahan et al., 2013), b) the beneficial 
effects on cognitive performance in chronic schizophrenic patients (Ehrenreich et al., 2007b) 
and c) the antidepressant-like effects of EPO in healthy individuals (Miskowiak et al., 2007a; 
2007b), we sought to answer the question of whether ARA290 exerts similar antidepressant-
like effects as EPO does. Since EPO was tested with the neuropsychological model of drug 
action, we applied the same model and experimental design (incl. frequency of ARA290 
administration and timing of testing). 
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The absence of distinct antidepressant-like effects in our study may be due to differences in 
pharmacokinetics between EPO and ARA290. In humans, EPO has an elimination half-life of 
approximately 5 hours (Eckardt et al., 1989; McMahon et al., 1990), whereas ARA290 has an 
elimination half-life of approximately 2 minutes following i.v. administration (Niesters et al., 
2013). Despite the short elimination half-life, ARA290 is suggested to pass rapidly into the 
CNS and elicit durable effects due to the activation of IRR which regulates the innate tissue-
protective response in various stages over a period from hours to days (Brines et al., 2008a; 
Brines and Cerami, 2012). Consistent with this, a phase 1 study in patients suffering from 
sarcoidosis or diabetes-induced neuropathy showed that ARA290 (i.v. 2 mg) administration 
for 3 days (spread over one week) reduced pain scores; an effect that lasted for 3 days 
following the last treatment (Niesters et al., 2013). Furthermore, first phase human studies 
with ARA290 indicated modest improvements in cognitive measures six hours after a single 
dose (Investigators brochure ARA290, 2009). Since first phase studies in humans did not raise 
safety concerns with the dose of 2 mg i.v. administration, we chose to administer the same 
dosage in our study. The time interval of measuring the antidepressant effects of ARA290 
was chosen based on the studies investigating the antidepressant effects of EPO by means 
of the neuropsychological model of drug action (i.e., 6-7 days post administration). It is, 
therefore, conceivable that we have missed some effects of ARA290 on emotional information 
processing and cognition in general due to 1) possibly incorrect timing of measurement and 
2) possibly ineffective dose of ARA290. An explanation for the lack of distinct antidepressant-
like effects may be that either the timing of measurements should have been shorter after 
a single dose of administration (e.g., 2-3 days post administration) and/or that the dose of 
ARA290 administration should have been higher or that repeated administration (e.g., three 
administrations of 2 mg spread over a week) is needed in order to produce detectable effects 
at cognitive level. 
Besides the differences in pharmacokinetics between EPO and ARA290, some limitations 
of the neuropsychological model also need to be addressed. The behavioural measures 
included in the test battery tap into different aspects of emotional information processing 
such as attention, memory and recognition of emotional facial expressions. Most of the 
stimuli used in these behavioural measures have an emotional content and are subject 
to habituation as well as learning effects. The majority of the tests included in the battery 
of emotional information processing can therefore be administered only once. Due to 
this restriction we chose not to take baseline measurements prior to the pharmacological 
intervention. In order to compensate for the lack of baseline measurements we increased 
the number of participants in our study (N=36). This is higher than the fMRI studies on EPO in 
healthy participants (N= 24)  (Miskowiak et al., 2007a), that also had no baseline assessments. 
Baseline measures would of course have provided objective measures of inter-subject 
variability and differences in response between groups prior to intervention. 
Another possible point of criticism relates to the design of the cognitive challenges during 







with prior research, the fMRI tasks in our study were presented in a block-design. Therefore, it 
is conceivable that we did not observe distinct differences in hippocampal function between 
groups during the picture recognition task as a block-design limits the possibility to analyse 
responses to individual trials. Presentation of trials in an event-related design would have 
made it possible to investigate the changes in hemodynamic response during correct and 
incorrect recognition of pictures. In a block-design, however, it is not possible to distinguish 
between correct vs. incorrect recognition. Consequently, changes in BOLD response 
associated with correct and incorrect recognition could not be modelled in the data. 
Overall, the effects of ARA290 on the neural response during task performance are task specific 
rather than a general effect of ARA290 on these regions, as ARA290 was not associated with 
changes in the functional connectivity of the brain. 
1c. Effects of ARA290 – Underlying biological mechanism
Although ARA290 seems to elicit changes in a few domains of emotional information 
processing, overall the results indicate that a single administration of ARA290 is not sufficient 
to initiate the explicit shift towards a more positive bias in emotional information processing 
as had been hypothesized based on the neuropsychological model we have applied. Possible 
limitations of our studies are discussed in paragraph 1b, however, the question that needs 
to be answered at this point is a) whether it is worthwhile to continue to study ARA290 as a 
therapeutic compound for depression, and if so b) which steps are needed in order to further 
investigate the potential of ARA290 as antidepressant drug.  
Our findings with a single administration of ARA290 in healthy individuals does not seem 
particularly promising as an antidepressant compound, however, when taking into 
consideration the positive findings reported in clinical trials with patients suffering from 
peripheral neuropathy together with the cellular pathways activated by ARA290, the 
antidepressant-like effects of ARA290 may need to be explored with a different approach.
ARA290 activates the IRR, a receptor which is locally up-regulated following tissue damage 
(Brines and Cerami, 2008b). In the brain, activation of the IRR leads to the activation of 
the STAT pathway (Fu et al., 2010; Brines and Cerami, 2012) which in turn results in the 
up-regulation of survival signals and the inhibition of inflammation-induced apoptosis 
(Brines and Cerami, 2012). Furthermore, activation of the STAT3 and STAT5 pathways in 
human neural stem cells facilitate the differentiation of neural stem cells and outgrowth of 
neurites (Fu et al., 2010). In rodents, ARA290 supresses the inflammation response in spinal 
microglia following nerve injury providing evidence for central anti-inflammatory actions 
of ARA290 (Swartjes et al., 2014). Also, phase 1 and 2 clinical trials in neuropathy patients 
indicate beneficial effects of ARA290 on pain symptoms (Niesters et al., 2013; van Velzen et al., 
2014) which are suggested to be mediated by the anti-inflammatory and tissue restorative 
actions initiated by ARA290 (van Velzen et al.,2014). Given these aforementioned findings, it 
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is conceivable that antidepressant-like effects of ARA290 occur and/or are only detectable 
in the “appropriate” biological environment, i.e. in individuals with increased levels of 
inflammatory biomarkers (i.e. elevated levels of pro-inflammatory cytokines). Inflammation 
has been proposed as one of the biological mechanisms underlying depression and has been 
recognized as a biological factor increasing the risk to develop MDD (as reviewed by Dantzer 
et al., 2008; Rosenblat et al., 2014), it is therefore possible that ARA290  exerts antidepressant-
like effects in a subgroup of individuals who are vulnerable to develop depression due 
to the presence of high inflammation bio-markers. Besides the limitations discussed in 
section 1b concerning proper timing of assessment following ARA290 administration, future 
studies would also benefit from examining the effect of ARA290 on depressive symptoms 
(e.g., fatigue, sleep disturbances, changes in appetite, mood and cognition) in biologically 
vulnerable populations (i.e., individuals who are at risk to develop MDD due to conditions of 
high inflammation). 
2a. Does L-tryptophan, a dietary compound, have antidepressant effects? 
The effect of prolonged (six days) intake of TRP on HPA-axis reactivity (cortisol response) 
and social decision making (response to unfairness) was examined in a sample selected on 
genotype (i.e., S’/S’ and L’/L‘ carriers of the 5-HTTLPR genotype). Our results indicate that 
TRP supplementation lowers the cortisol response to social stress in S’/S’ carriers of the 
serotonin transporter gene while it has no effect on the cortisol response in L’/L’ carriers. TRP 
supplementation for six days had no effect on mood or on symptoms of anxiety and depression 
in either of the genotype groups. The same study indicates that TRP supplementation does 
not influence the behavioural response to unfairness in the ultimatum game (UG). A non-
significant difference was found in the opposite direction as expected: the tryptophan-group 
had higher rejection rates of very unfair offers than the placebo group.  Also, 5-HTTLPR 
genotype did not influence the behavioural response to unfairness. 
2b. Effects of L-tryptophan – Limitations  
The beneficial effects of tryptophan on stress response in healthy volunteers appears to be 
specific for a certain genotype, i.e., the S’/S’ variant of the 5-HTTLPR. Tryptophan did not 
have an effect on social decision making in either (L’/L’ or S’/S’) variant of the  5-HTTLPR 
genotype. 
The response to unfairness in the ultimatum game in healthy subjects appears to be under 
serotonergic control as acute tryptophan depletion was associated with a higher rejection 
rate of very unfair offers (Crockett et al., 2008), whereas a single dose of the selective serotonin 
reuptake inhibitor (SSRI) citalopram (30 mg) was associated with a lower rejection rate of 
unfair offers (Crockett et al., 2010). Our study showed that tryptophan supplementation for 







TRP group seemed to reject very unfair offers more often if the stakes were relatively high, 
which is in the opposite direction as expected based on the findings of Crockett et al. (2010). 
However, the effect was a non-significant in our study. S’/S’ carriers of the 5-HTTPLR were 
expected to reject more offers (regardless the of level of unfairness) prior to treatment and 
were expected to benefit from the TRP supplementation in order to make more utilitarian 
decisions by lower rejection rates of unfair offers. However, 5-HTTPLR genotype did not 
influence the response to unfair offers. 
In our study we did not draw blood samples pre- and post TRP supplementation to prevent 
possible interference with the cortisol response to the stress induction (i.e. Trier Social Stress 
Task). Although plasma TRP is an indirect measure of central serotonin availability, the lack 
of TRP plasma ratios pre- and post TRP supplementation complicates the interpretation of 
the null findings. Several possibilities could have been excluded if we would have measured 
plasma TRP levels. The last TRP intake was on the evening of the 6th day and the UG was 
performed on day 7. This may have turned our intended TRP supplementation into a relative 
depletion of TRP compared to the six days of supplementation prior to the day of testing. 
Oral TRP administration 50 mg/kg (3.5 g for 70 kg – mixed in milk) to humans showed that 
TRP concentration in blood reaches a peak approx. after 6 hours and returns to its baseline 
value after 12 hours, whereas, in the cerebrospinal fluid the peak is reached earlier (between 
six and ten hours) and returns to baseline after approx. 18 hours (Eccleston et al., 1970). This 
early study of Eccleston et al. (1970) was carried out with a small sample size and needs to be 
interpreted with caution. However, even if a relative depletion was caused by the interruption 
of TRP supplementation at the day of testing, this may have pushed TRP levels back to 
baseline but would not cause the sizeable drop in TRP concentrations that is reached with 
an ATD procedure (i.e., approx. 70-90% drop from baseline, see review Van der Does, 2001). In 
addition, the effect we expected from prolonged TRP supplementation on ultimatum game 
behaviour was based on the idea of the cognitive neuropsychological model of Harmer 
et al. (2009) which hypothesizes that the neuro-adaptive effects of antidepressant agents, 
together with social interactions occur in parallel and reshape emotional biases which lead 
to a shift from negative to positive biases. In line with this hypothesis, TRP supplementation 
was expected to lead to a positive switch in which participants would be able to overrule 
their negative emotion towards unfair offers and would be able to make utilitarian 
decisions. Furthermore, at the same day of testing (i.e., day 7) we still observed an effect 
of TRP supplementation on the cortisol response to social stress in S’/S’ carriers. Perhaps, 
in contrast to HPA-axis reactivity, social decision making and social cognition in general is 
more dependent on absolute TRP levels (i.e. acute increase or decrease in TRP availability). 
The studies that have shown the effect of serotonin availability on social decision making 
were interventions in which the effect of manipulating serotonin availability (either by means 
of  SSRI’s, TRP loading or depletion) was measured quickly after (approx. 1-2 hours) a single 
administration (Crockett et al., 2008; 2010; Colzato et al., 2013). 
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Another possible methodological limitation may be the absence of dietary instructions 
on the day of testing itself (i.e., day 7). We asked participants to refrain from food intake 1 
hour before arrival to the laboratory, however, more specific instructions (e.g. restricting 
protein rich food) regarding their food intake before arrival (i.e., for breakfast or lunch) to the 
laboratory may have been beneficial in order to control the possible drop in TRP availability 
to the brain due to  competing amino acids. 
Although we did find an effect of TRP supplementation on the cortisol response in S’/S’ 
carriers, one could argue that our study was underpowered to detect genetic effects on 
social decision making as genetic studies require larger sample sizes (Review, Burmeister et 
al.,2008). Also, our parallel design, in combination with the number of participants may not 
have yielded enough power to replicate the pharmacological effects on the UG as Crockett 
et al. (2008) and Crockett et al. (2010) has found with a cross-over design, which has a larger 
statistical power. 
Overall, our study may have benefitted from biological measures related to TRP metabolism. 
Although plasma TRP/LNAA ratio is a peripheral and indirect measure of TRP availability, 
plasma measures pre- and post-intervention  a) would have given more insight in the 
possible explanation underlying the lack of behavioural effects on the UG following a 6-day 
TRP supplementation and  b) would have revealed possible non-compliance, although the 
latter being very unlikely given the findings on the physiological level (Cerit et al. 2013). 
2c. Effects of L-tryptophan – Underlying biological mechanism
The effects of tryptophan are rather well known as most of the early studies have investigated 
its additive antidepressant effects in combination with conventional antidepressant drugs 
or with electroconvulsive therapy (Coppen et al., 1963; 1967; 1972; D’Elia et al., 1977a,b; 
Møller et al., 1980). Although research on the antidepressant properties of tryptophan 
has diminished due to the introduction of SSRIs (Parker and Brotchie, 2011), the effects 
of increasing serotonin availability on emotional information processing and mood are 
relatively well documented (Booij et al., 2006; aan het Rot et al., 2006). Therefore, in contrast 
to our ARA290 study - in which we directly applied the neuropsychological model of drug 
action in order to examine its antidepressant effects for the first time in healthy individuals - 
in the tryptophan study we included alternative measures in order to examine the beneficial 
effects of tryptophan in healthy individuals. Social decision making and HPA-axis reactivity 
were of special interest as both measures have been shown to be sensitive to serotonergic 
manipulations either induced by experimental interventions (TRP loading or depletion) or 
serotonergic antidepressants (Crocket et al., 2008; 2010; Markus and Firk, 2009).
Tryptophan supplementation lowered the cortisol response to acute stress in S’/S’-carriers. 
The involvement of the serotonin system in the control of the HPA axis during an acute stress 







et al., 2000; Lepage et al., 2002). The generally accepted view is that the serotonergic system 
is not an unitary system and has a stimulating as well as an inhibiting role in the regulation 
of a stress response (McAllister – Williams et al., 1998; Markus et al., 2000). The stimulatory 
effect of serotonin on the HPA-axis activity is mediated through 5HT1A and 5HT2a and 
5-HT2c receptors in the hypothalamic paraventricular nucleus and the pituitary (McAllister 
– Williams et al., 1998; Lowry, 2002), while the inhibiting effect of serotonin is mediated 
through 5-HT1A receptors in the hippocampus where serotonin exerts negative feedback 
control over the HPA axis (McAllister – Williams et al., 1998; Markus et al., 2000). Although 
the exact mechanism of the serotonergic control over the HPA axis is unclear, an imbalance/
disturbance in the  interaction between the two systems results in an inadequate biological 
response to stressful situations making it difficult to cope with stress (Markus et al., 2000). 
Sufficient serotonergic activity during stressful situations is thought to be essential for an 
adequate biological response and stress adaptation (Markus et al., 2000). Based on this 
premise Markus et al., (2000) hypothesized that stress-prone individuals, defined as having 
high neuroticism scores, are subject to a constant lack of serotonin availability due to chronic 
stress exposure, and consequently, possess a hypersensitive serotonergic system. Stress-
prone individuals with a hypersensitive serotonergic system are therefore expected to benefit 
from a diet that increases the TRP/LNAA ratios, and presumably central serotonin. Such diet 
would also result in a normalized HPA-axis activity/stress response, as indexed by a reduced 
cortisol response when exposed to acute stress (Markus et al., 2000). The authors suggested 
two possible mechanisms of how increased serotonergic activity in stress-prone individuals 
may be involved in the control of the HPA-axis (i.e. reduced cortisol response): 1)  Increasing 
serotonin availability may act on the serotonergic innervations of the hippocampus by 
the median raphe nucleus. It is known that serotonin in the hippocampus exerts negative 
feedback control over the HPA axis (Jacobson 1991; Markus 2000). Hippocampi with higher 
serotonergic sensitivity, as assumed to be the case in stress-prone individuals, may exert a 
stronger negative feedback on the HPA axis following increased TRP availability. As a result 
of this, a reduction of cortisol release will follow due to more pronounced inhibiting action 
of serotonin. 2) Increasing serotonin availability may lead to enhanced activation of higher 
cortical structures such as the prefrontal cortex, thereby increasing their control over limbic 
adreno-cortical system (Markus et al., 2000).
Although these proposed underlying mechanisms remain speculative, the short variant of 
the 5-HTTLPR is associated with less serotonin uptake activity, leaving more serotonin in 
the synaptic cleft compared to the long variant. The 5HT1A auto-receptor is an important 
regulator in the serotonergic system and continuous stimulation of the 5HT1A receptor by 
5HT in s/s carriers may decrease 5-HT synthesis and release resulting in shortage of 5-HT 
availability, similarly as has been shown for the mechanism of action of antidepressants 
(Blier and de Montigny, 1998). Assuming that the short allele carriers have a hypersensitive 
serotonergic system due to chronic shortage of serotonin availability (i.e. serotonergic activity 
is reduced by the inhibitory feedback of 5HT1A receptors), sub chronic administration of TRP 
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may have normalized the reduced serotonergic activity. The normalization of serotonergic 
activity, in either the serotonergic innervations of the hippocampus or enhanced higher 
cortical control over limbic adrenocortical structures, may have resulted in normalization of 
cortisol response in S’/S’ carriers of the 5-HTTTLPR genotype. 
The underlying neural mechanism of the sensitivity to acute stress in S’/S’ carriers of the 
5-HTTLPR has been investigated by applying unpredictable electric shocks in healthy 
women during fMRI scanning (Drabant et al., 2012). During anticipation to acute stress, S’/S’ 
carriers exhibited an enhanced activation in the amygdala, hippocampus, anterior insula, 
thalamus, pulvinar, caudate, precuneus, anterior cingulate cortex, and the medial prefrontal 
cortex (mPFC) compared to L’-allele carriers (Drabant et al., 2012). Although no increase of 
central serotonin availability was induced and no direct or indirect measures of HPA-axis 
were included, this study showed that brain structures involved in the processing of threat 
are more active during acute stress in S’/S’ carriers, possibly due to a lack of (serotonergic) 
control of higher cortical structures over these limbic subcortical structures.
While a large meta- analysis on the effect of 5-HTTLPR on antidepressant efficacy concluded 
that 5-HTTLPR does not predict antidepressant response in MDD patients (Taylor et al., 
2010), another meta- analysis found that in Caucasians (but not in Asians), the L allele was 
associated with higher probability of response and remission when treated with SSRIs 
(Porcelli et al., 2012). The finding that L allele carriers are more responsive to SSRIs, seems to 
contradict with our finding that tryptophan supplementation did not have an effect on the 
cortisol response during stress in L-allele carriers, while it did attenuate the cortisol response 
in S-allele carriers. Our study was conducted in a Caucasian population and although 
both tryptophan and SSRIs influence serotonergic neurotransmission, they are different 
interventions. SSRIs act on the serotonin transporter in order to block the re-uptake of 
serotonin from the synaptic cleft, whereas tryptophan is a precursor of serotonin. Besides its 
role in the brain, tryptophan metabolism occurs in other tissues, and it contributes to various 
bodily functions including immune response and intestinal functions (Le Floc’h et al., 2011). 
Furthermore, the aforementioned meta-analyses have a focus on treatment response in 
patients, whereas our study has focussed specifically on the HPA axis reactivity as indexed by 
cortisol response to acute social stress in healthy individuals. These differences between the 
two interventions (antidepressant drugs and tryptophan) and the different focus of the meta- 
analysis (i.e. reduction of symptoms in patients), make it difficult to extrapolate the findings 
regarding 5-HTTLPR and SSRI efficacy to our study conducted with six days of tryptophan 
supplementation. In general our findings support the notion that variation of 5-HTTLPR 
genotype is associated with altered reactivity to serotonergic manipulations.
3. General Conclusion 
The cognitive neuropsychological model has been proposed as a complementary tool 







expensive RCTs (Harmer et al., 2009; 2011). The effects of ARA290 were small and not all of 
these were in the expected direction of an antidepressant-like effect. Future studies may 
benefit from repeated ARA290 administration over time, and/or a shorter period between 
administration of ARA290 and testing. Furthermore, regardless of the model applied, it 
is essential to take into account the “biological environment” in which the compound is 
expected to exert an effect. In the future ARA290, as an anti-inflammatory compound, may 
be administered to healthy but depression vulnerable individuals as determined by high 
inflammation biomarkers. The beneficial effects of ARA290 may be more distinct when 
tapped into a specific (biological) vulnerability factor (i.e. inflammatory conditions). 
Tryptophan lowered the cortisol response to stress only in S’/S’ carriers of the 5-HTTLPR 
genotype while it did not affect the L’/L’, which indicates a beneficial, although not necessarily 
an antidepressant effect, of tryptophan in a specific genetically vulnerable group. The effect 
of tryptophan on social decision making was not modulated by 5-HTTLPR genotype. In the 
future the modulation of social decision making by 5-HTTLPR genotype may be investigated 
by means of acute interventions (i.e. acute increase in TRP availability) rather than prolonged 
interventions (i.e. six days).
The potential of  (human) experimental medicine models in predicting antidepressant drug 
efficacy may be improved by a) defining system-specific biological vulnerability factors 
implicated in the aetiology of depression together with the selection of the population 
based on these biological vulnerability factors, and by b) targeting biomarkers specific to the 
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Het testen van de effectiviteit van farmaca is een langdurig proces dat uit verschillende fases 
bestaat. Deze fases omvatten proefdieronderzoek, onderzoek in kleine aantallen vrijwilligers 
en uiteindelijk onderzoek bij patiënten voor wie het farmacon bedoeld is. Het sluitstuk 
van dit proces vormt het testen van het geneesmiddel in grootschalige gerandomiseerde 
gecontroleerde trials (randomized clinical trials; RCTs). Hierin worden de effecten van het 
middel vergeleken met placebo of met een reeds bekend middel. Het afronden van het 
hele proces duurt vaak meer dan tien jaar en het komt geregeld voor dat pas in de laatste 
fase (bij de RCTs) de effectiviteit onvoldoende blijkt. Er is dus behoefte aan gevoeligere 
indicatoren voor effectiviteit, die al in de eerdere fasen van het testen van farmaca duidelijker 
aanwijzingen geven over welke middelen het meest veelbelovend zijn om in grootschalige 
RCTs te testen. 
In het geval van antidepressiva laten de RCTs zien dat ook de reeds geregistreerde middelen 
matig effectief zijn. Een RCT met de serotonine heropname remmer (SSRI) sertaline in 
chronische depressie patiënten resulteerde, na een behandeling van 12 weken, in een 
respons rate van 22%  (d.w.z. minimaal 50% reductie in symptomen) en een remissie rate van 
36% (d.w.z. reductie van symptomen tot beneden de diagnose drempel) (Keller et al., 1998). 
Een ander voorbeeld is een observationele studie waarbij behandeling met citalopram 
resulteerde in een respons rate van 47% en een remissie rate van 28-33% na 8 weken (Trivedi 
et al., 2006). Dit betekent dat ongeveer 50% van de patiënten met een chronische depressie 
niet reageren op antidepressiva (Keller et al., 1998; Trivedi et al., 2006). Meta-analyses van 
gerandomiseerde gecontroleerde trials wijzen uit dat antidepressiva de symptomen van 
depressie verbeteren, maar dat het verschil met placebo klein is. Dit verschil is alleen van 
klinisch belang in patiënten met een ernstige depressie (bij wie placebo minder effectief is) 
(Khan et al., 2002; Kirsch et al. 2008; Fournier et al., 2010). 
Samenvattend, er is een noodzaak voor het ontwikkelen van nieuwe en effectievere 
antidepressiva voor de behandeling van depressie. Zoals hierboven vermeld, loopt het 
proces van het ontwikkelen van nieuwe medicatie vaak stuk in de laatste fase, die van 
grootschalige en dure gerandomiseerde klinische trials. Dan blijkt een medicijn dat 
aanvankelijk veelbelovend leek – in diermodellen of open trials met kleine aantallen 
proefpersonen –  toch niet voldoende effectief te zijn (Harmer et al., 2011). Hierdoor is er 
behoefte aan experimentele modellen, die (vóór de fase van grootschalige klinische trials) als 
preklinische instrumenten ingezet kunnen worden om de effectiviteit van nieuwe medicijnen 
beter te kunnen onderzoeken en een mogelijke potentie beter te kunnen voorspellen. 
Hiertoe zijn er verschillende experimentele modellen beschreven die relevant zijn voor 
medicijnontwikkeling voor psychiatrische stoornissen (Dawson et al., 2011). Een van deze 
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modellen is het cognitieve neuropsychologische model van antidepressiva (Harmer et al., 
2009; 2011). 
In dit proefschrift worden studies gepresenteerd waarbij gebruik is gemaakt van dit cognitieve 
neuropsychologische model. Een studie (Hoofdstuk 1 en 2) had als doel om de antidepressieve 
werking van een potentieel nieuw antidepressivum te onderzoeken, de neuropeptide 
ARA290. De tweede studie (Hoofdstuk 3 en 4) betrof een bestaand voedingssupplement 
(tryptofaan, precursor van serotonine). Tryptofaan (TRP) is verkrijgbaar zonder recept en 
word reeds veelvuldig ingenomen als voedingssupplement (bijv. om beter te kunnen slapen). 
In tegenstelling tot ARA290, is veel meer bekend over het effect van TRP op de cognitie welke 
een gerichtere toepassing  van het neuropsychologisch model toeliet. Het effect van ARA290 
is onderzocht met behulp van een standaard cognitieve testbatterij. Het effect van tryptofaan 
is onderzocht in een genetische kwetsbare groep waarin de  fysiologische respons op sociale 
stress is gemeten en een aangepaste cognitieve testbatterij, waaronder een test voor sociale 
cognitie. 
 Beide studies vonden plaats in een gezonde populatie, omdat kwetsbaarheidmarkers 
van depressie (zoals die gezien worden in depressie patiënten die in remissie verkeren) ook 
gemeten kunnen worden met farmacologische interventies in gezonde populaties  (Harmer 
et al., 2003; Harmer et al., 2008; Arnone et al., 2009; Murphy et al., 2009; Rawlings et al., 2010). 
Een bijkomend voordeel is ook dat gezonde deelnemers niet lijden aan een huidige vorm 
en ook geen geschiedenis hebben van een psychiatrische stoornis waardoor de respons 
op de interventie niet gecontamineerd is door eerder farmacologische behandeling(en). 
Deze eigenschappen maken een gezonde populatie geschikt voor het onderzoeken van de 
effecten van een nieuwe interventie in een experimenteel psychologische setting. 
Cognitieve neuropsychologische model van antidepressiva
Bestaande antidepressiva hebben soms 6-12 weken nodig om een klinisch effect te laten 
zien in patiënten met een depressie, maar blijken direct effect te hebben op de verwerking 
van emotionele informatie - zelfs na eenmalige toediening in gezonde vrijwilligers  (Harmer 
et al., 2003; Harmer et al., 2008; Arnone et al., 2009; Murphy et al., 2009; Rawlings et al., 2010). 
Het neuropsychologisch model beschrijft dat deze vroege meetbare effecten een gevolg zijn 
van de directe biologische veranderingen in verschillende processen op moleculair niveau, 
die gelijk na inname van antidepressiva plaatsvinden (Figuur 1). De initiatie van deze directe 
effecten (zoals bijvoorbeeld de toename van serotonine in de synaptische spleet) leiden op 
hun beurt weer tot een cascade aan neuro-adaptieve processen, maar ook tot een overgang 
van een voornamelijk negatieve bias naar een (meer)  positieve bias in de verwerking van 
emotionele informatie (Review Harmer et al., 2009). Volgens het neuropsychologisch 
model vindt er een interactie plaats tussen geïnduceerde neuro-adaptieve processen en 
veranderingen in de verwerking  van sociaal-emotionele stimuli uit de omgeving, welke na een 







naar een meer positieve verwerking van sociaal-emotionele stimuli is tevens geassocieerd 
met neurale veranderingen in subcorticale en corticale circuits die gedetecteerd kunnen 
worden door middel van MRI-technieken (Review, Harmer et al., 2009).
Figuur 1. Onderliggende mechanisme van de vertraagde klinische effect van antidepressiva als voorgesteld 
door het neuropsychologisch model (Harmer et al., 2009).
Het cognitieve neuropsychologische model bestaat uit een reeks aan cognitieve en 
neurale maten die het doel hebben om  de vroege antidepressieve effecten te meten in 
gezonde vrijwilligers en hierdoor een betere schatting te maken van de potentie van een 
antidepressieve interventie. De testen (ofwel taken) waarvan in dit model gebruik wordt 
gemaakt, richten zich op het oppikken van de verschuiving van een negatieve bias naar een 
meer positieve bias in de verschillende processen die een rol spelen in het verwerken van 
emotionele informatie zoals bijv. aandacht en geheugen (Review Harmer et al., 2009). 
Naast de bestaande gedrags- en neurale maten van dit model zijn in het onderzoek, dat 
in deze dissertatie is beschreven, maten meegenomen die specifiek gericht zijn op het 
mechanisme van de beoogde interventie (nl. tryptofaan). Een van de meest bestudeerde 
genetische variaties die gerelateerd is aan depressie, is een allelvariatie in de promotor regio 
van de serotonine transporter gen: het serotonine transporter polymorfisme (5-HTTLPR) 
(Heils et al., 1996). Afhankelijk van de combinatie van de allelen (kort of lang) in de promotor 
regio van het serotonine transporter gen worden er meer of minder serotonine transporters 
tot expressie gebracht in de membranen van de presynaptische neuronen, wat op zijn beurt 
een invloed heeft op de serotonine neurotransmissie (Canli &  Lesch, 2007). Naar de relatie 
tussen 5-HTTLPR en stress respons is veel onderzoek gedaan vanwege de a) rol van het 
serotonerge systeem in depressie b) rol van de hypothalamus-hypofyse-bijnier-as (HHB-as; 
Engels: HPA-axis) reactiviteit in depressie en c) de interactie tussen het serotonerge systeem 
en de HPA-axis in het reguleren van de neuro-endocriene responsen. Meerdere studies 
hebben laten zien dat de HPA-axis reactiviteit verschilt afhankelijk van de variant van het 










Figuur	  1.	  	  Onderliggende	  mechanisme	  van	  de	  vertraagde	  klinische	  effect	  van	  antidepressiva	  als	  voorgesteld	  
door	  het	  neuropsychologisch	  model	  (Harmer	  at	  al.,	  2009).	  
	  
Het	  cog itieve	  n uropsyc ologische	   odel	  bestaat	  uit	  een	  reek 	  aan	  cognitieve	  en	  neurale	  maten	  
die	  het	  doel	  hebben	  om	  	  de	  vroege	  antidepressieve	  effecten	  te	  meten	  in	  gezonde	  vrijwilligers	  en	  
hierdoor	  een	  betere	  schatting	  te	  maken	  van	  de	  potentie	  van	  een	  antidepressieve	  interventie.	  De	  
testen	  (ofwel	  taken)	  waarvan	  in	  dit	  model	  gebruik	  wordt	  gemaakt,	  richten	  zich	  op	  het	  oppikken	  van	  
de	  verschuiving	  van	  een	  negatieve	  bias	  naar	  een	  meer	  positieve	  bias	  in	  de	  verschillende	  processen	  
die	  een	  rol	  spelen	  in	  het	  verwerken	  van	  emotionele	  informatie	  zoals	  bijv.	  aandacht	  en	  geheugen	  
(Review	  Harmer	  et	  al.,	  2009).	  	  
Naast	  de	  bestaande	  ge rags-­‐	  en	   eurale	  mat n	  van	  dit	  m del	  zijn	  in	  het	  onde zoek	  dat	  in	  
deze	  dissertatie	  is	  beschreven	  maten	  meegenomen,	  die	  specifiek	  gericht	  zijn	  op	  het	  mechanisme	  van	  
de	  beoogde	  interventie	  (nl.	  tryptofaan).	  Een	  van	  de	  meest	  bestudeerde	  genetische	  variaties	  die	  zijn	  
gerelateerd	  aan	  depressie	  is	  een	  allelvariatie	  in	  de	  promotor	  regio	  van	  de	  serotonine	  transporter	  gen:	  
het	  serotonine	  transporter	  polymorfisme	  (5-­‐HTTLPR)	  (Heils	  et	  al.,	  1996).	  Afhankelijk	  van	  de	  
combinatie	  van	  de	  allelen	  (kort	  of	  lang)	  in	  de	  promotor	  regio	  van	  het	  serotonine	  transporter	  gen	  
worden	  er	  meer	  of	  minder	  serotonine	  transporters	  tot	  expressie	  gebracht	  in	  de	  membranen	  van	  de	  
presynaptische	  neuronen,	  wat	  op	  zijn	  beurt	  een	  invloed	  heeft	  op	  de	  serotonine	  neurotransmissie	  












analyse laat zien dat er een associatie bestaat tussen het 5-HTTLPR genotype en HPA-axis 
reactiviteit in respons op stress, waarbij de homozygoot kortere variant  (met een minder 
efficiënte serotonine neurotransmissie) een hogere cortisol respons laat zien (Miller et al., 
2012). Behalve HPA-axis reactiviteit is het 5-HTTLPR genotype ook geassocieerd met een 
variatie in verwerking van emotionele informatie (Perez-Edgar et al., 2010; Antypa et al., 
2011; Koizumi et al., 2013). In deze dissertatie zijn 5-HTTLPR genotype samen met HPA-
axis reactiviteit en sociale-emotionele informatie verwerking geïncludeerd als maten die 
specifiek gericht zijn op de beoogde interventie: tryptofaan.  
Samenvatting van de bevindingen
Wij onderzochten de antidepressieve effecten van ARA290 (i.v. 2 mg) op gedrags- en neurale 
(functionele MRI) maten gerelateerd aan de verwerking van emotionele informatie in gezonde 
proefpersonen (N= 36) (Hoofdstuk 2). Deze placebo gecontroleerde studie werd dubbelblind 
en gerandomiseerd (in parallel groep design) uitgevoerd. ARA290 groep liet (t.o.v. placebo 
groep) een verlaagde neurale (BOLD) respons zien in de bilaterale gyrus fusiformis tijdens het 
verwerken van blije gezichten, terwijl het verwerken van angstige gezichten een verhoogde 
neurale activiteit liet zien in de rechter gyrus fusiformis. Op de gedragsmaten leek de ARA290 
groep (t.o.v. placebo groep) gezichtsexpressies van blijdschap en walging minder goed te 
herkennen. Hoewel ARA290 niet geassocieerd is met een beter geheugen voor positieve 
woorden, vonden we wel een associatie van ARA290 met snellere categorisatie van positieve 
vs. negatieve woorden. De ARA290 groep liet (t.o.v. placebo) tevens een verhoogde aandacht 
voor emotioneel positieve plaatjes zien. We vonden geen effecten van ARA290 op stemming 
of affectieve symptomen. In dezelfde groep hebben we het effect van ARA290 op resting-
state activiteit onderzocht (Hoofdstuk 3).  Een week na eenmalige toediening heeft ARA290 
geen effect op a) de connectiviteit van de acht standaard netwerken (beschreven zijn door 
Beckmann et al., 2005) en b) de vooraf gedefinieerde seed regio’s (hippocampus/amygdala 
en gyrus fusiformis).
Uit Hoofdstuk 2 blijkt dat ARA290 enige aspecten van het verwerken van emotionele 
informatie moduleert, echter, de richting en de sterkte van de effecten ondersteunen niet 
een eenduidig antidepressief effect. Aangezien ARA290 geen invloed heeft op depressie 
gerelateerde netwerken, kan worden geconcludeerd dat de cognitieve effecten van ARA290, 
zoals beschreven in Hoofdstuk 2, niet gemedieerd worden door een effect op functionele 
connectiviteit. 
Toekomstig onderzoek zou het effect van hogere doseringen en kortere tijdsinterval op 
functionele connectiviteit moeten uitwijzen. Vanwege de anti-inflammatoire eigenschap van 
ARA290, is het mogelijk dat effecten van ARA290 gemedieerd worden door anti-inflammatoire 
acties binnen het centrale zenuwstelsel. Toekomstig onderzoek zou zich daarom kunnen 
richten op het onderzoeken van de cognitieve effecten van ARA290 in populaties waar sprake 







antidepressiva met klinisch relevante effecten mede bemoeilijkt wordt door heterogeniteit 
van depressie, zou onderzoek naar de cognitieve effecten van ARA290 in een subgroep 
van depressie patiënten (waarin de aanwezigheid van hoge inflammatie bio-markers een 
belangrijke rol spelen) meer licht kunnen werpen op de effectiviteit en het onderliggende 
antidepressieve mechanisme van ARA290. 
In Hoofdstuk 4 onderzochten we de  effecten van tryptofaan inname gedurende zes dagen 
(2.8 g/d) op HPA-axis reactiviteit in gezonde proefpersonen (N=46) die dragers zijn van het 
homozygoot korte (S’/S’) of homozygoot lange (L’/L’) variant van de serotonine transporter 
polymorfisme (5-HTTLPR). Deze placebo gecontroleerde studie werd dubbelblind en 
gerandomiseerd (in parallel groep design) uitgevoerd. Zes dagen na tryptofaan of placebo 
inname werd in alle proefpersonen stress geïnduceerd middels een sociale stressor (Trier 
Social Stress Taak) en cortisol gemeten als een maat voor HPA-axis reactiviteit. TRP verlaagt 
de cortisol respons na blootstelling aan sociale stress in de S’/S’ groep, terwijl TRP geen 
effect heeft op de cortisol respons in de L’/L’groep. Tryptofaan lijkt de acute stress respons in 
een genetisch kwetsbare groep te normaliseren, hetgeen kan duiden op een antidepressieve 
werking. Hoewel tryptofaan suppletie een effect heeft op fysiologie, lijkt het geen effect te 
hebben op socio-emotionele informatieverwerking welke is gemeten met de  Ultimatum 
Game (Hoofdstuk 5). Deze taak vereist het vermogen om een initiële emotionele reactie op 
een oneerlijk bod van de tegenspeller te overwinnen ten behoeve van eigen baat. Hoewel 
de TRP groep neigde naar meer weigering van onrechtvaardige aanbiedingen van de 
tegenspellers was deze bevinding niet significant. Ook blijkt 5-HTTLPR genotype geen rol te 
spelen. 
Conclusie 
In deze dissertatie is het cognitieve neuropsychologische model toegepast als preklinisch 
instrument om de effectiviteit van mogelijke antidepressieve middelen te kunnen voorspellen. 
ARA290 heeft effect op enkele domeinen van emotionele informatie verwerking, echter, 
de richting en de sterkte van de effecten ondersteunen niet een eenduidig antidepressief 
effect. Tryptofaan lijkt de cortisol respons in een genetisch kwetsbare groep te normaliseren, 
hetgeen kan duiden op een antidepressieve werking. De potentie van preklinische 
experimentele modellen t.b.v. het voorspellen van effectiviteit van (nieuwe) antidepressieve 
middelen zouden verbeterd kunnen worden door het zorgvuldig definiëren van biologische 
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